Skip to content
naulon
Get started

No retraction, correction or concern found when last checked on Oct 26, 2026.

Current Progress on Epidemiology, Diagnosis, and Treatment of Sporotrichosis and Their Future Trends

Anderson Messias Rodrigues, Sarah Santos Gonçalves, Jamile Ambrósio de Carvalho and 3 more

Journal of Fungi · 2022 · Review · CC BY

doi:10.3390/jof8080776

Abstract

Sporotrichosis, a human and animal disease caused by Sporothrix species, is the most important implantation mycosis worldwide. Sporothrix taxonomy has improved in recent years, allowing important advances in diagnosis, epidemiology, and treatment. Molecular epidemiology reveals that S. brasiliensis remains highly prevalent during the cat-transmitted sporotrichosis outbreaks in South America and that the spread of S. brasiliensis occurs through founder effects. Sporothrix globosa and S. schenckii are cosmopolitan on the move, causing major sapronoses in Asia and the Americas, respectively. In this emerging scenario, one-health approaches are required to develop a creative, effective, and sustainable response to tackle the spread of sporotrichosis. In the 21st century, it has become vital to speciate Sporothrix, and PCR is the main pillar of molecular diagnosis, aiming at the detection of the pathogen DNA from clinical samples through multiplex assays, whose sensitivity reaches remarkably three copies of the target. The treatment of sporotrichosis can be challenging, especially after the emergence of resistance to azoles and polyenes. Alternative drugs arising from discoveries or repositioning have entered the radar of basic research over the last decade and point to several molecules with antifungal potential, especially the hydrazone derivatives with great in vitro and in vivo activities. There are many promising developments for the near future, and in this review, we discuss how these trends can be applied to the Sporothrix-sporotrichosis system to mitigate the advance of an emerging and re-emerging disease.

Full text

From PubMed Central, U.S. National Library of Medicine, as current on Oct 26, 2026. Paragraph numbers are ours, so an answer can point at one.

1. A Brief Introduction to the System Sporothrix-Sporotrichosis

Sporotrichosis is a subcutaneous mycosis caused by the dimorphic fungus Sporothrix schenckii and related species, which are found worldwide in vegetation, decaying organic matter, Sphagnum moss, and soil. Sporotrichosis is transmitted through traumatic inoculation of Sporothrix propagules into skin tissue. The classical transmission route refers to sapronosis (i.e., environment to warm-blooded vertebrate host). Therefore, it is an occupational mycosis usually associated with trauma during outdoor work in gardeners, farmers, extractivist, and florists, among others. The alternative route of infection is related to horizontal animal transmission, mainly affecting domestic cats and armadillos. In the cat-transmitted sporotrichosis, these animals spread the disease through scratches and bites or direct contact with their secretions to other cats, causing epizootics, or directly to humans (zoonosis).

Most cases of human sporotrichosis manifest in the skin and subcutaneous tissues. The disease may vary according to the immune status of the infected host, with the lymphocutaneous form being the most common manifestation (~80% of cases). The fungus spread to bones and viscera is uncommon and occurs more frequently in immunosuppressed patients, especially in AIDS. Pulmonary sporotrichosis, resulting from the inhalation of fungal propagules (conidia or yeasts), is uncommon.

Cats are the most susceptible hosts to contamination by Sporothrix and commonly develop the most severe forms of the disease, which can progress to death. Multiple ulcerative lesions are usually observed in the cephalic region, mainly in the nose and paw region, due to feline behavior that involves scratching and biting during fights. Sporotrichosis is higher among adult male cats, without owners, and those not neutered. Different from what occurs in lesions in humans, a high number of yeasts can be observed in felines.

Spontaneous cure of human and animal sporotrichosis is rare, and treatment with antifungals is indispensable for most patients. Although localized sporotrichosis is readily treated, managing osteoarticular sporotrichosis, disseminated visceral forms, and feline sporotrichosis is laborious.

For over a century, S. schenckii sensu lato was described as the sole agent of human and animal sporotrichosis. However, advances in molecular taxonomy revealed that it is not a monotypic taxon. Sporothrix comprises approximately 53 species, including S. brasiliensis, S. schenckii, S. globosa, and S. luriei, forming a clade of clinical interest as they are frequently recovered from cases of sporotrichosis. The other Sporothrix species are embedded in the environmental clade and show little or no virulence to the warm-blooded vertebrate host. Strictly environmental Sporothrix species are often associated with soil, insects, and plants. However, we highlight the members of the S. pallida complex (S. chilensis, S. gemella, S. humicola, S. mexicana, S. pallida, S. palmiculminata, S. protea-sedis, and S. stylites) which include soil-inhabitants fungi with mild-pathogenic potential for humans and animals (Figure 1).

The differential pathogenicity in Sporothrix may be related to the efficiency in the temperature-induced morphological transition. Thermal dimorphism is an important morphological adaptation for infection, shared with other human pathogens, phylogenetically distant in the Onygenales and Eurotiales. Sporothrix species nested in the clinical clade are ‘professional’ thermodimorphic fungi responding more efficiently to thermal stimuli. In addition, S. brasiliensis express important virulence attributes such as thermotolerance, adhesins, and melanin, being the most virulent species in murine models such as BALB/c, C57BL/6, and OF-1 mice. Such exacerbated virulence in animals is also observed in the human host, and S. brasiliensis is associated with atypical and more severe forms of the disease, including disseminated skin infection in immunocompetent hosts and systemic disease.

2. Trends in the Epidemiology of Sporothrix Species

Sporotrichosis is a cosmopolitan mycosis whose etiological agents are constantly on the move. Species of clinical interest are not evenly distributed worldwide, and many are associated with different transmission routes. No official statistics show the burden of human and animal sporotrichosis globally, but only case series denounce the problem. Therefore, it is a fact that sporotrichosis has classically been a mysterious disease from an epidemiological point of view.

Notoriously, the history of sporotrichosis shows repeated manifestations in the form of outbreaks and epidemics. The most famous epidemic occurred in the mid-1940s in South Africa, where more than 3000 native Bantu miners were infected with Sporothrix growing in the soil and the supporting timbers of the Witwatersrand gold mines. Recently, to a lesser extent, a new case series was described in South Africa, showing that the fungus can persist in nature for decades. In South Africa, sapronotic transmission of the disease predominates, where S. schenckii s. str. is the main agent identified by molecular methods. Animal sporotrichosis is rare in Africa, and environmental isolation shows the presence of members of the S. pallida complex. Data on the occurrence of sporotrichosis on the African continent are scarce, being reported mainly in Madagascar, Zimbabwe, Nigeria, and Sudan. In these areas, there is no correlation between the incidence of sporotrichosis and the HIV/AIDS epidemic. Despite a discreet series, the reports from the 1940s were fundamental for understanding the sapronotic route of the disease, clarifying, for the first time, the ecoepidemiological aspects of sporotrichosis.

On the Asian continent, epidemiological data arise mainly from Japan, China, India, and Malaysia, where there is a predominance of cases of human sporotrichosis due to S. globosa. Human sporotrichosis is endemic in India, occurring with high prevalence in the northern sub-Himalayan region, from Himachal Pradesh in the northwest to Assam and West Bengal in the east. Historically, sporotrichosis was very common in Japan between the 1940s and 1980s, with significant remission since then. In this country, molecular epidemiology was significantly influenced by RFLPs and PCR-RFLPs analysis of mtDNA, which revealed two main clades, groups A and B. Currently, the reinterpretation of epidemiological data in light of taxonomic changes in Sporothrix confirms that S. globosa (group B) was the main agent of human sporotrichosis in Japan in the 1980s, followed by S. schenckii s. str. (group A).

The incidence of human sporotrichosis in China is among the highest globally. Cases are concentrated in the northeast region of China, in an area with a temperate continental monsoon climate, including Jilin, Liaoning, and Heilongjiang provinces. Interestingly, there is a higher incidence of cases during the winter, possibly associated with contamination of the home environment with wood, twigs, and sticks used as an important energy matrix for cooking and heating. Therefore, similar to epidemics in Africa, in Asia, sporotrichosis is a sapronosis whose main transmission route is the traumatic inoculation of plant material. However, unlike what happens in Africa, the etiological agent is S. globosa. The exception to the rule is Malaysia, where S. schenckii s. str. can cause epizootics in domestic cats, increasing zoonotic transmission levels.

Human sporotrichosis was common on the European continent at the beginning of the last century. The cases emerged mainly in France and were richly reported in the literature. However, the disease has decreased its incidence considerably since then, with rare case reports mainly from the United Kingdom, Spain, and Italy. Notwithstanding, with the introduction of S. brasiliensis in England, our attention should be focused on the evolution of the number of cases in the coming years.

In Australia, sporadic reports of human sporotrichosis do not exceed a few hundred infections. Australian cases are generally associated with S. schenckii s. str. and S. globosa following a sapronotic route, mainly in Queensland, New South Wales, and Western Australia. In these areas, outbreaks of sporotrichosis attributed to environmental sources such as hay are not uncommon. Feline sporotrichosis is rare in Australia, as described in the mid-1980s. New cases have now been associated with S. pallida in cats, an even rarer association.

Sporotrichosis is relatively common in the Americas. In the USA, where the disease was first described in 1898, S. schenckii s. str. causes illness in professionals linked to agricultural activities such as rose gardeners and farmers. The largest reported outbreak in the USA occurred in 1988 and affected 84 patients in 15 states exposed to the fungus in mosses of the genus Sphagnum, used in gardening procedures. In the USA, between 2000 and 2013, 1471 hospitalizations were reported in patients with opportunistic conditions such as HIV/AIDS, immune-mediated inflammatory diseases, and chronic obstructive pulmonary disease.

In Latin America, sporotrichosis emerges as the most common implantation mycosis, with areas of high endemicity in Brazil, Colombia, Peru, and Venezuela. However, we noticed significant differences that reflect on the species transmitted and on the route of transmission of the disease. For example, the sapronotic route of sporotrichosis is common throughout Latin America, where S. schenckii s. str. and S. globosa are spread through contact with fungal propagules present in the environment. On the other hand, the zoonotic route of sporotrichosis is more common in Brazilian territory, where cat-transmitted sporotrichosis is the main type of infection for humans, dogs, and other cats, and S. brasiliensis is the major agent in these cases.

Case reports of human sporotrichosis occur in 25 of the 26 Brazilian states. However, due to the emergence of sporotrichosis in cats, there is a marked temporal variation concerning the succession of species involved in transmissions (Figure 2). Before the 1990s, the classical sapronotic transmission of human sporotrichosis prevailed, similar in Latin American countries. After the 1990s, with the entry of the domestic cat into the sporotrichosis transmission chain, it is possible to detect a considerable increase in epizootic manifestations in felines and zoonotic transmission to humans. This scenario has the metropolitan region of Rio de Janeiro as its epicenter, and between the 1990s and 2000s we observed a gradual spread of the epidemic to other states in the South and Southeast regions. Recently, in full expansion, we described the emergence of S. brasiliensis in the northeast region of the country, mainly in the states of Pernambuco, Paraíba, and the Rio Grande do Norte. Interestingly, in these areas of feline sporotrichosis, S. schenckii s. str. is no longer the main transmitted species, and S. brasiliensis becomes the main agent during the cat-transmitted sporotrichosis events (Figure 2).

Judging from a public health point of view, the major drawback in the above scenario is the absence of a national notification system to report disease cases. Since 2011, the notification of sporotrichosis has been mandatory in the State of Rio de Janeiro, but not in other Brazilian states, with rare specific exceptions at regional and municipal levels.

In general terms, the geographic fluctuation of sporotrichosis agents is fascinating. Sporothrix globosa is the predominant molecular type in Asia. S. schenckii s. str. is highly prevalent in Australia, South Africa, western South and Central America, and North America. Sporothrix brasiliensis is highly prevalent in Brazil. Among all medically relevant Sporothrix species, S. brasiliensis has the greatest potential for geographic dispersal. In areas where it occurs, S. brasiliensis easily outperforms other clinically relevant species due to feline transmission. To date, Argentina and Paraguay have reported the occurrence of S. brasiliensis in humans and cats outside Brazil, and there are suspected cases in Bolivia, Colombia, and Panama. Recently, a zoonotic case was reported in the UK after a veterinarian treated a cat with sporotrichosis imported from Brazil. In the absence of official epidemiological data, case reports show the importance of the disease, its local and regional escalation, and the urgent need to establish sanitary barriers to mitigate the advance of S. brasiliensis and the cat-transmitted sporotrichosis.

In feline sporotrichosis, it is generally accepted that a single diseased cat introduced to a new location can trigger an outbreak that will quickly evolve into an epidemic. A new dissemination area may include locations as close as a neighborhood, a new city, or even more distant areas such as other states. Introducing diseased animals to new areas has occurred repeatedly within the natural history of cat-transmitted sporotrichosis. The metropolitan region of Rio de Janeiro is described as the possible center of origin, from where the disease initially spread to other border states in the southeastern region (e.g., São Paulo, Espírito Santo, and Minas Gerais) and later to the southern region. (e.g., Paraná). The most recent migration event occurred towards the Brazilian northeast in mid-2015 (Figure 3).

De Carvalho and colleagues reported that cat-transmitted sporotrichosis progresses through founder effects (Figure 3). In population genetics, a founder effect refers to the reduction in genetic variability that occurs when a small group of individuals not genetically representative of the parental population migrates to a new area and establishes a new population. Over time, the resulting new subpopulation will have genotypes and phenotypic characteristics similar to the founding individual, which may differ greatly from the parent population. Therefore, a founder effect may explain, for example, the low genetic diversity found during the initial outbreaks of cat-transmitted sporotrichosis. However, the absence of sanitary barriers and the constant introduction of sick animals (parental population → founder population) to new areas can reconstitute genetic diversity in the founder population, leading to comparable genetic diversity.

Cats adapt to a wide range of environments, and in general, the roaming area of domestic cats (0.02–10 ha) overlaps with the human residential area, where they can more easily secure food. Therefore, the only viable hypothesis to justify the detection of a genotype from the parental population of Rio de Janeiro in areas as remote as the state of Pernambuco in the northeast region (>2000 km) is the introduction of sick cats via humans who migrate with their pets, since sporotrichosis is not a disease of direct person-to-person transmission or even a zooanthroponosis. This hypothesis may also explain the introduction of sick cats in other South American countries, such as Argentina and Paraguay, or even the European continent, as recently reported in England. Establishing sanitary barriers to contain the migration of sick felines is a fundamental measure for controlling the expansion of S. brasiliensis (Figure 3).

The recent outbreaks in Brazil due to cat-transmitted sporotrichosis and the widespread expansion in South America are important reminders of how human and non-human health are essentially connected. Animals are the source of 70% of emerging and re-emerging infectious disease threats to human health and more than half of all recognized human pathogens. We observed that the recent entry of the domestic cat into the transmission chain of sporotrichosis associated with the emergence of S. brasiliensis, a more virulent species adapted to animal transmission, produced a significant revolution in the classical epidemiological pattern, confirming that such threats are dynamic.

Although the absence of official and reliable data makes it difficult to measure the problem, cat-transmitted sporotrichosis is responsible for a significant burden of sporotrichosis in Brazil. Geoepidemiological analyses of zoonotic sporotrichosis cases in Rio de Janeiro, Brazil, reveal that the social determinants of the disease are linked to social vulnerability. The disease mainly affects women (25 to 59 years old), especially in socioeconomically disadvantaged neighborhoods of Rio de Janeiro, expressed by low per capita income and deficient supply of treated water to households. This shows that sporotrichosis can be aggravated in scenarios of greater social vulnerability, a regretful development that tends to be repeated in other areas of the country.

Therefore, a public health problem that encompasses human, animal, and environmental health issues requires solutions based on one-health approaches (Figure 4). One-health approaches consider the interactions among different spheres of global health to develop a creative, effective, and sustainable response. Therefore, interdisciplinary research is mandatory, as is interventionist practice at local, national, and international levels, involving public managers, physicians, veterinarians, biologists, public and animal health authorities, environmental health agents, and microbiologists, among other allies.

The current Brazilian environmental scenario results from climate change, intense deforestation, and biodiversity loss. The Intergovernmental Panel on Climate Change’s sixth assessment report reveals that a 1.5 °C rise in global temperature would result in a 100–200% increase in the population affected by floods in Colombia, Brazil, and Argentina, 300% in Ecuador, and 400% in Peru (medium confidence). Higher temperatures, heavy rainfall, and flooding are associated with an increase in emerging zoonotic diseases. Medically relevant Sporothrix can be detected in the soil of endemic areas where it remains for years, and it is interesting to hypothesize that water from floods and inundations, a phenomenon increasingly common in Brazil, may also promote the diffusion of Sporothrix propagules in the soil.

In this chaotic scenario, we incorporate the fact that in endemic areas, cats with sporotrichosis are often buried directly in the soil, producing latent foci of the pathogen. Soil functions as the main reservoir of fungal propagules and certainly does not act as a passive reservoir. The advance of deforestation in the Amazon, Cerrado, and Atlantic Forest is worrying, leading to biodiversity loss in these biomes. It is known that soil microbial composition can be altered due to deforestation, reflecting co-occurrence patterns among microorganism taxa, leading to ecological imbalance. For example, soil amoebas (e.g., Acanthamoeba castellanii) rapidly change the composition of the bacterial community in the soil, and it is well known that many of these protozoa interact with Sporothrix, predating the microorganism in the soil. Therefore, it is expected that environmental stresses (e.g., higher temperatures, humidity, pH, etc.) that affect A. castellanii in the soil, leading to alterations in biodiversity, may reflect population imbalances in the fluctuation of Sporothrix species (Figure 4).

These scenarios demonstrate that one-health solutions are complex to implement in their totality, yet they are crucial to combat the spread of emerging Sporothrix species (Figure 4).

3. Trends in the Diagnosis of Sporotrichosis

Sporotrichosis can be diagnosed through a correlation of clinical, epidemiological, and laboratory data. The early and accurate laboratory diagnosis of sporotrichosis is of substantial importance since the clinical aspect of cutaneous lesions can mimic other dermatologic manifestations, such as mycobacteriosis, actinomycosis, American tegumentary leishmaniasis, blastomycosis, cryptococcosis, paracoccidioidomycosis, among others. In addition, ulcerative lesions can mimic pyoderma gangrenosum. Clinical suspicion and the patient’s epidemiological context are key to assembling this puzzle and thus promptly establishing the diagnosis.

The diagnosis of sporotrichosis is based on the isolation and identification of Sporothrix in culture, cytopathology, histopathology, sporotrichosis skin test, serology, immunohistochemistry, and molecular techniques. Moreover, complementary laboratory tests such as blood count and biochemical profile should be requested in systemic forms. Anemia, neutrophilic leukocytosis, gammopathies, and hypoalbuminemia are commonly observed.

3.1. Mycological Test

Currently, the reference method for sporotrichosis diagnosis remains the isolation and identification of microorganisms in culture media and characterization of the agent by morphological parameters. Although it has been widely used in clinical routine, the method sensitivity is not 100%, which can generate false-negative results due to contamination of the samples with bacteria and anemophilous fungi and inadequate transport of the material. While considered a low-cost diagnosis, it is noteworthy that it is not suitable for diagnosing atypical and extracutaneous forms of the disease.

Depending on the clinical form and laboratory approaches, several biological samples can be investigated. The most frequent specimens are tissue fragments, serosanguineous exudates, purulent secretion, scraping of hyperkeratotic crusts, aspirate of lymph nodes, and organ fragments obtained during necropsy. It must be emphasized that some care must be observed not to attenuate the technique sensitivity, such as material transport temperature, time storage, and appropriate clinical sample processing.

To ensure the fungus viability, some criteria should be pursued, including (i) seed the material as soon as possible in culture media; (ii) transport swabs on Stuart media; (iii) preserve tissue fragment biopsies in sterile saline solution (mycological tests) or formalin solution (histological examinations). Furthermore, the sooner the biological material is seeded in culture media, the greater the chances of recovery of the microorganism. Otherwise, amid eventualities, the clinical sample should be kept at 4 °C for a time less than 8–10 h.

The average growth time of Sporothrix spp. in mycelial form (25 °C) is 3–5 days to two weeks. The isolates obtained can be accurately identified from positive cultures, and antifungal susceptibility testing in vitro and other assays can be performed. Macroscopically, in media such as malt extract agar (MEA) or potato dextrose agar (PDA), the colonies start to grow as hyaline filamentous fungi and then turn brown to black after a few days, mainly in the colony’s center. Sometimes the mycelium can grow entirely white, designated as an albino. The Sporothrix colonies’ diameter is smaller, ranging from 19 to 41 mm, compared to other filamentous fungi, such as Aspergillus fumigatus (65–70 mm). Microscopically, the mycelial form is observed as septate, thin, branched, and hyaline hyphae, with conidiogenous cells arising from undifferentiated hyphae, forming conidia thick-walled (hyaline or brown), small (2–3 × 3–6µm), with a different arrangement, such as sympodial form, appearing in small groups of denticles in a slight apical dilation of the conidiophore or as sessile.

Sporothrix is a thermodimorphic fungus. To ensure its identification, it is recommended to stimulate the morphological transition. The fungus should be seeded in enriched media such as blood glucose-cysteine agar or Brain Heart Infusion agar (BHI) and subsequent incubation at 35–37 °C to obtain the yeast form. The growth time is the same as the mycelial form. In some cases, the isolates grow slowly, so the fungi should be incubated for up to 30 days for the outcome. In yeast form, the colonies are tan or cream-colored and smooth. Micromorphologically, it is possible to observe spindle-shaped and oval cells measuring 2.5–5 μm in diameter, like cigar-shaped buds on a narrow base.

Although the phenotypic characterization is not distinctly effective to speciate Sporothrix, it allows the presumptive identification of some species belonging to the clinical clade. Some characteristics, such as the color and shape of conidia, suggest some clinical species, such as S. brasiliensis and S. schenckii s. str.. The latter predominates more elongated conidia, and some isolates showed triangular pigmented conidia, thereof being characteristic of the species. Concerning S. brasiliensis, the conidia are mostly more globose dematiaceous conidia, yet they may have the presence or absence of melanin. Micromorphological characteristics may also hint at identifying S. chilensis, S. mexicana, and S. pallida, commonly environmental species, with mid-pathogenic potential for humans. All these aspects are subtle, and their variations can lead to errors in identifying the species.

Marimon et al. and Rudramurthy et al. demonstrated that physiological characteristics such as growth rate, thermotolerance, and sugar assimilation might be helpful in the differentiation of morphologically similar species embedded in the clinical clade. Besides, some studies imply that medically relevant Sporothrix can be distinguished from environmental, according to the analysis of growth rates and thermotolerance. Although not entirely elucidated, clinical strains probably have specific characteristics acquired during their evolution that undoubtedly contributed to their pathogenicity.

Toward accurately speciating Sporothrix, the polyphasic approach is most advisable for assembled morphological, physiological, molecular, and ecological characteristics. Whereas culture remains a reference in the sporotrichosis diagnosis, the delayed results may impact the severity and compromise the disease treatment, decreasing the probability of cure in cats and humans and improving the transmission risk.

3.2. Direct Microscopic, Cytopathological, and Histopathological Examinations

Biological material obtained from human skin lesions and tissue fragments has a low fungal burden, and the yeast size (2–6 μm) hinders their visualization in the direct microscopic examination (DME) of fresh material. Thus, DME of samples treated with potassium hydroxide solution (KOH, 10–30%) or with fast staining techniques should not be recommended. However, the DME shows better positivity in immunosuppressed patients. The DME specificity and sensitivity of the tissue samples are still unknown, as most investigators consider this tool inefficacious.

According to Orofino-Costa et al., purulent secretion imprints or biopsies stained with Giemsa increase the test’s sensitivity in humans. In extracutaneous forms, the DME sensitivity is even lower; occasionally, it is possible to observe the fungal structures in cigar or shuttles forms.

Cytopathological examination stained with periodic acid-Schiff (PAS) or Gomori-methenamine silver (GMS), the aspiration puncture of the lesions, especially in the extracutaneous and disseminated forms, eventually allows the observation of granuloma of epithelioid cells, asteroid bodies, and yeast cells. In 20% of cases, asteroid bodies may be observed in the center of the granuloma. Asteroid bodies are globular or oval yeast cells surrounded by radiated eosinophilic material (Splendore-Hoeppli reaction), including antibodies (IgM and IgG), with the role of defense against phagocytes.

Findings of asteroid bodies in the stained cytopathological examination are very unpredictable since it depends on the staining method and displays minor reproducibility. It is not a sporotrichosis pathognomonic structure, as it may be observed in other granulomatous and infectious diseases. Gram, Giemsa, PAS, and GMS may be successfully used in disseminated manifestations.

Conversely, Gram, quick Panoptic, Wright, Giemsa, or Rosenfeld cytopathological staining techniques are more sensitive in animals, particularly felines (Figure 5A). The cytopathological examination from exudates and skin lesions shows a high fungal burden, making it possible to observe Sporothrix yeast cells that range from being rounded, oval, or cigar-shaped, surrounded by a transparent, capsule-like halo, as seen in Cryptococcus spp. and Histoplasma spp.. These structures may be disposed of inwardly in macrophages, neutrophils, and multinucleated or free giant cells. Concerning feline sporotrichosis, asteroid bodies are uncommon.

The quick Panoptic method, a Romanowsky-type staining technique like Diff-Quik, has become relatively common in veterinary clinics due to its practicality, low cost, and great return (Figure 5B,C). A staining kit profits around 1000 slides. This diagnosis has a sensitivity of 52.6% to 95% in cats compared to culture, the reference method. However, for non-ulcerated or low exudative lesions, treatment with antifungals in high doses seems to interfere negatively with this method’s sensitivity. In the last years, the feline sporotrichosis laboratory diagnosis starts with cytology by imprinting the lesions in glass slides and isolating the fungus in culture. In this scenario, an old-fashioned method such as cell block cytology achieves an impressive 97.5% sensitivity when diagnosing feline sporotrichosis during outbreaks and epidemics.

As in cytopathology, the histopathological findings in human samples may be nonspecific, only signaling the human sporotrichosis diagnosis. The paucity of fungal structures is also similar. The histopathological pattern is associated with granulomatous and pyogenic reactions, which may lodge with epidermal hyperplasia (with or without ulceration), papillomatous acanthosis, hyperkeratosis, intraepidermal microabscess, and fungal elements such as yeast cells and asteroid bodies. In approximately 50% of cases, the yeasts may be visible in tissue smears stained with PAS and GMS. Briefly, the granuloma caused by Sporothrix may show three distinct zones: (i) center with abscesses or necrosis (central zone); (ii) area with granulomatous inflammation constituted by giant cells (tuberculoid zone); and (iii) lymphocytes and plasm cells, with granulation tissue and fibrosis (syphiloid zone). The inflammatory infiltrates are best observed by hematoxylin-eosin (HE) staining. In patients with AIDS, the histopathological findings are uncommon; the inflammatory response is lower, and there is no presence of asteroid bodies. However, the amount of yeast is profuse.

3.3. Serology

The first serological tests for sporotrichosis diagnosis were performed in 1910 using tube agglutination (TA) and complement fixation (FC) tests. The tests using precipitins were described in 1947, employing a polysaccharide antigen. In 1973, Blumer et al., besides testing these methods, also evaluated immunodiffusion (ID), slide agglutination test (SLA), and indirect fluorescent antibody (IFA). At that time, the SLA and ID methods were the most specific. SLA had the highest sensitivity (94%), proving to be an easy-to-perform technique that generates quick results and is highly recommended for clinical routine.

Sporotrichin, an antigenic complex consisting of a peptide-rhamnomannan, is obtained from a crude extract of the mycelial phase of S. schenckii sensu lato. This antigenic fraction was developed for intradermal skin reactions to measure the degree of immunity or receptivity of the individual with suspected disease, determining first contact with the fungus without developing the disease. Sporotrichin has a long history in surveillance studies depicting areas of high endemicity.

The absence of a standardized or commercial antigen impacts the serological diagnosis of sporotrichosis in Europe and the USA. Nevertheless, sporotrichin effectiveness in highly endemic regions ranges from 89 to 96%, making it an interesting additional test. Bonifaz et al. reported that false-positive results might be attributed to patients in constant contact with the agent, such as those who live in endemic areas or cases in which the patient preserves immunological memory. However, false-negative points correspond to patients with different immunosuppression degrees.

Many attempts have been made to adopt serological tests such as sporotrichosis diagnostic methods, given that they are fast, highly accurate, and not invasive. The fungal cell wall antigens and anti-cell wall antibodies became the main target of studies searching to develop serological tools that are more sensitive and specific.

It is well known that S. schenckii displays a mixture antigen complex, including peptide-rhamnomannan, a cell wall glycoconjugate (CWPR) of the yeast phase of the fungus. This structure can be fractionated by affinity chromatography on Sepharose 4B with concanavalin A (Con A), generating two fractions: one binding to Con A (SsCBF) and the other non-binding to Con A (SsNBF). The fraction bound to Con A is relevant for serological diagnosis. Besides, techniques such as immunoblot, fluorescent antibodies, counterimmunoelectrophoresis (CIE), double immunodiffusion (DID), and enzyme-linked immunosorbent assays (ELISA) have been quoted as auspicious.

A study by Penha and Lopes-Bezerra, using the ELISA method, evaluated 35 patients with the sporotrichosis cutaneous form, and SsCBF showed 100% specificity with the investigated sera. Subsequent studies have also demonstrated high levels of sensitivity and specificity for the various clinical presentations of human sporotrichosis, including extracutaneous, lymphocutaneous, fixed, and disseminated forms.

Bernardes-Engemann et al. validated the ELISA test applying purified antigenic fraction SsCBF for the human sporotrichosis diagnosis by detecting the anti-SsCBF immunoglobulin G (IgG) antibody fraction. Thus, 177 serum samples from different clinical forms were evaluated. The investigators observed high specificity (82%) and sensitivity (89%) with a reproducibility of 98%, including for emerging species such as S. brasiliensis, and may be made disposable for routines of the health services.

One year after that, Alvarado et al. evaluated the potential of the crude antigen obtained from the mycelial form of S. schenckii s. str. in serum from sporotrichosis patients by applying different methods, including DID, CIE, and ELISA. The assays were validated using serum from disease patients such as paracoccidioidomycosis, histoplasmosis, leishmaniasis, tuberculosis, lupus, and serum from healthy patients. Investigators achieved 100% sensitivity and >98% specificity for all tests.

Fernandes et al. evaluated ELISA’s test using SsCBF and an exoantigen for the domestic cats’ serological assay with suspected sporotrichosis. The authors reported 90% sensitivity and 96% specificity for SsCBF. Excellent results were also reached by Rodrigues et al., testing different antigen types obtained from crude extracts of S. schenckii s. str. and S. brasiliensis yeast cells. The results suggest that the ELISA technique with distinct antigens may be applied in diagnosing feline sporotrichosis. Furthermore, all the antigens studied reacted similarly, with no significant difference in titer. Therefore, the results generated by antigens of the different etiological agents should probably not interfere, likely because antigenic epitopes are shared and well conserved between S. schenckii and S. brasiliensis.

Baptista et al. recently validated felines serology; however, it has been available only in private clinics and laboratories. The authors modified the SsCBF-ELISA test for human serological diagnosis and the quantification of IgG antibodies for all clinical forms of feline sporotrichosis.

Recombinant Sporothrix antigens have also been studied as diagnostic markers, and in 2019, Martinez-Alvarez and colleagues evaluated an ELISA test for the human sporotrichosis detection from a recombinant glycoprotein obtained from the cell wall of S. schenckii, Gp70. Nonetheless, the findings were not as promising for the diagnosis compared to the SsCBF antigen.

The hyperepidemic worsening of feline and human sporotrichosis has reached proportions in different regions and countries. Public policies should be established to contain the disease, and new diagnostic methods should be developed to prevent the spread of sporotrichosis. Therefore, serological methods can qualitatively and quantitatively evaluate the condition, generating fast results with high levels of specificity and sensitivity. It would already be a big step, as it would directly impact the diagnosis of the disease and the diagnostic screening and therapeutic monitoring of human and animal sporotrichosis, including those who develop atypical and severe forms.

3.4. Molecular Diagnosis

For the last decades, the classical identification of the species belonging to the Sporothrix genus was based only on phenotypic methods. Although these methods supply reduced cost, they are laborious, time-consuming between collection and final diagnosis, and do not allow to speciate Sporothrix since they have overlapping morphological and physiological features. It is essential to highlight that the phenotypic plasticity in Sporothrix may exist even intraspecifically.

With the advance and improvement of molecular tools, it is possible to identify, reclassify, and recognize new species of fungi, allowing a greater understanding of the biology of these microorganisms. Regarding the molecular identification of Sporothrix, some critical points should be considered; among them, we highlight the type of sample (e.g., soil, biopsy, isolated culture, exudate, vegetable), the cost of technique, the time that the process is executed, sensitivity/specificity, and DNA quality. The advances in molecular diagnosis of sporotrichosis were recently reviewed by de Carvalho et al..

The polymerase chain reaction (PCR) and its variants are widely used in human and feline sporotrichosis diagnosis. It is possible to carry out DNA amplification using several molecular markers and different methods depending on the proposed objective from clinical specimens and fungi obtained from growth in culture. Kano et al. pioneered the non-culture-dependent PCR technique. From human tissue, they identified S. schenckii sensu lato using chitin synthase I (CHS1) as a target gene to amplify DNA. In 2003, Kano and collaborators applied this same technique in biopsy samples obtained from six patients with human sporotrichosis, confirmed by histopathology and mycological findings. The generated DNA fragments showed 99% similarity with S. schenckii reference strain.

After that, other molecular tools with the potential to detect the Sporothrix DNA directly from environmental samples (soils, plants, decaying wood, tree bark) and clinical specimens obtained from humans and animals (biopsy, skin lesion, aspirate of abscess, exudate swabs, and pus) were proposed. The most frequently used techniques have been species-specific PCR (Figure 6A), nested PCR, restriction fragment length polymorphism (RFLP), and qPCR (quantitative real-time PCR). Among the different targets, the most common are 18S rRNA, Large Subunit (LSU), internal transcribed spacer (ITS), β-tubulin (BT2), calmodulin (CAL), and mitochondrial DNA genes. Nevertheless, it is worth mentioning that few techniques allow for detecting Sporothrix DNA from clinical samples and identifying it down to a species level.

Della-Terra et al. developed and evaluated a multiplex qPCR assay for sporotrichosis diagnosis exploiting polymorphisms found in the β-tubulin gene (Figure 6B). Samples of cat lesions and environmental samples spiked with S. brasiliensis, S. schenckii, and S. globosa propagules were used to reveal the feasibility of the method to detect Sporothrix DNA. High specificity (100%) and sensitivity (98.6%) were reported. Moreover, the technique did not show cross-reaction with other pathogenic fungi, human, feline, or murine DNA, allowing the identification of all major Sporothrix species in a single tube. The key advantages of the multiplex qPCR assay include decreasing amount of reagents, reduction of the process steps, greater sensitivity when compared to culture, species-specific PCR, rolling circle amplification (RCA), and other qPCR assays.

Regarding identifying and recognizing cryptic species belonging to Sporothrix, the reference method is DNA sequencing (Sanger) followed by phylogenetic analysis. In addition to amplification and partial sequencing of the ITS region (ITS1/2+5.8s), protein-coding loci such as BT2, translation elongation factor (EF-1α), and CAL should be included. Nowadays, the region between exons 3 and 5 of the CAL gene is the primary marker for identifying clinical species for this genus.

Techniques like CAL-RFLP, RCA, and species-specific PCR can also identify Sporothrix down to species level. The major difference among methods is that RCA and species-specific PCR can detect Sporothrix DNA, whereas CAL-RFLP was designed for strains isolated in culture.

DNA fingerprint methods such as amplified fragment length polymorphisms (AFLPs) have demonstrated broad applicability in speciating pathogenic fungi and describing genetic diversity. AFLP is widely used in evolutionary, population, epidemiological, and conservation studies of different taxa. AFLP’s main advantage is the simultaneous assessment of several loci, randomly distributed throughout the genome, without prior knowledge of the DNA sequence. This makes the AFLP singularly helpful for species with no genomic knowledge, and a powerful tool to be used to explore Sporothrix genetic diversity, answer questions related to the structure of the population, transmission routes, intra and interspecific variability, as well as modes of recombination and reproduction, among many other biological issues.

In the last decades, mass profiles of ribosomal proteins generated by Matrix-Assisted Laser Desorption/Ionization Time-of-Flight Mass Spectrometry (MALDI-ToF MS) have been a powerful tool in yeast identification in routine clinical laboratories. In recent years, MALDI-ToF MS databases have been built and expanded to identify filamentous fungi; for the technique to be reliable, rapid, and economical, databases must be accurate. The method was standardized to speciate Sporothrix isolates growing in vitro during the yeast phase, which allows the recognition of S. brasiliensis, S. schenckii, S. globosa, S. luriei, and members of the S. pallida complex. Furthermore, speciation by MALDI-ToF or DNA sequencing methods are in full agreement. However, the greatest limitation of MALDI-TOF relies on the need for prior culture. Only a few reports in the literature use this methodology to speciate Sporothrix. Matos et al. constructed an in-house database enriched with spectra generated from reference Sporothrix strains, enabling the identification of an isolate from S. brasiliensis obtained from a patient with subconjunctival infiltrative injury in a right eye.

Despite the relevance of molecular diagnostic tools, unfortunately, these techniques are not widely available in health services, being restricted to research laboratories and reference centers, thus negatively impacting the diagnosis of the disease.

4. Trends in the Treatment of Sporotrichosis

The treatment choice for sporotrichosis depends on the disease’s clinical form, the host’s immunological status, and the species Sporothrix involved. The most virulent species (S. brasiliensis, S schenckii, and S. globosa) exhibit different susceptibility profiles to antifungals; thus, the response to therapy can be variable.

Sporotrichosis was first described in 1898 when specific antifungal drugs were unavailable, and potassium iodide (KI) was used for several infectious and non-infectious diseases. KI saturated solution has been used for treating sporotrichosis since 1903. KI has immunomodulatory activity; it can suppress the production of toxic intermediates from oxygen by the polymorphonuclear leukocytes and, therefore, exert its anti-inflammatory effect. KI’s ability to directly destroy microorganisms is still a matter of speculation. Notwithstanding, reports in the literature suggest that when Sporothrix yeasts are exposed to increasing drug concentrations, cell lysis occurs through the release of lysosomal enzymes. Recent studies show that KI inhibits biofilm development in Sporothrix. The main adverse events of KI are metallic taste and nausea, followed by an acneiform eruption. Nowadays, its use in humans has been replaced by itraconazole, but due to its low cost, it is still used to treat cutaneous human forms and felines, in association or not with itraconazole.

Itraconazole started to be used in sporotrichosis treatment in the late 1980s, during the advent of the triazoles generation. Itraconazole is the drug of choice due to its effectiveness, safety, and posologic convenience for lymphocutaneous and cutaneous sporotrichosis. In Brazil, it is also used in animal treatment. Itraconazole is a fungistatic drug that inhibits the synthesis of ergosterol, the main sterol from the fungus cell membrane (Figure 7). Depending on the disease severity and the host’s immunological status, the therapeutic dose may range from 100 to 400 mg/day. Although it has good efficacy, treatment with itraconazole can cause several side effects and interact with more than 200 other drugs, inducing adverse events or lacking effectiveness. The main adverse effects reported are headaches and gastrointestinal disorders. It is also hepatotoxic, teratogenic, and embryotoxic, and may not be used in patients with liver diseases or pregnant women.

Another inhibitor of ergosterol synthesis used for sporotrichosis treatment is terbinafine (Figure 7). This allylamine treats cutaneous form in humans when itraconazole or KI is not tolerated or cannot be used. It is available in 125 and 250 mg tablets, facilitating pediatric administration. The recommended dose is 250 mg/day, but it may increase to 500 mg/day for adults.

In severe life-threatening cases, amphotericin B (deoxycholate or, preferably, liposomal, because such formulation has fewer adverse effects) is recommended until clinical improvement has been achieved, when it should be replaced with itraconazole. Amphotericin B is a polyene antifungal drug developed in the 1950s. There are four models proposed for the polyene mode of antifungal action: (i) the pore-forming model, (ii) the surface adsorption model, (iii) the sterol sponge model, and (iv) the oxidative damage model. In every suggested model, the binding of the polyene with ergosterol is essential to its antifungal effect (Figure 7). The total cumulative dose recommended for amphotericin B ranges from 1 to 3 g. Although effective and acts with fungicidal properties, treatment with amphotericin B is not recommended for cutaneous and lymphocutaneous sporotrichosis because of its high toxicity and the inconvenience of intravenous administration.

Although the sporotrichosis treatment is mainly based on the prescription of the antifungals described above, other commercial drugs can also inhibit the Sporothrix growth in vitro. Table 1 shows the activities of different commercial antifungals according to the minimum inhibitory concentration (MIC) values obtained in vitro by the broth microdilution methods described by the Clinical and Laboratory Standards Institute. Most of these antifungals are not used in treating sporotrichosis and are only used in the topical treatment of other fungal infections. Amphotericin B, itraconazole, and terbinafine exhibit higher in vitro activity against Sporothrix cells, with MIC described in the literature as lower than 1 µg/mL (Table 1).

Little is known about in vivo activity of other azoles for sporotrichosis treatment (Table 1), except for voriconazole and posaconazole. Voriconazole exhibits modest efficacy, while posaconazole is effective against disseminated sporotrichosis murine models. Although they have been used for other fungal infections, they are not currently used for sporotrichosis treatment.

Non-pharmacological measures are also used in treating sporotrichosis with good results, such as cryosurgery and thermotherapy. Cryosurgery is indicated when a slow itraconazole response is observed for the resolution of chronic lesions and when adverse effects lead to interruption of the antifungals. Local hyperthermia and cryosurgery are safe and efficacy options for treating pregnant women with cutaneous sporotrichosis. Photodynamic therapy could also be applied as a non-pharmacological treatment for sporotrichosis, considering the promising in vitro and in vivo studies; however, further clinical observation is still necessary.

In recent years, there has been an increase in therapeutic failures in treating sporotrichosis and reports of isolates with low sensitivity to itraconazole. The decrease of itraconazole effectiveness against S. brasiliensis observed in clinical isolates from Brazil over the last years could be related to resistance mechanisms developed by this species, such as overexpression of efflux pumps (Figure 4). The increased expression of efflux pumps in the fungal membrane reduces the antifungal activity due to the extrusion of the drug, decreasing its effect. The overexpression of efflux pumps corresponds to the main mechanism of acquired resistance to azoles in fungi of medical relevance. However, other resistance mechanisms could be related to S. brasiliensis decreasing susceptibility to itraconazole, such as melanin production and overexpression or mutation of the target enzyme. On the other hand, studies investigating new molecules with anti-Sporothrix activity have increased.

We performed a retroactive literature search for studies published between 2012 and July 2022 using the databases Cortellis Drug Discovery Intelligence (https://www.cortellis.com/drugdiscovery/ (accessed on 14 July 2022) and PubMed (https://pubmed.ncbi.nlm.nih.gov/ (accessed on 14 July 2022), with “Sporothrix” as the Keywords. We considered promising compounds with MIC against Sporothrix species less or equal to 4 µg/mL or 1 µM, as determined by Clinical and Laboratory Standards Institute protocols. Based on these criteria, we found seventeen new molecules or repositionable drugs over the last ten years (Table 2). Most studies listed in Table 2 are Brazilian research papers highlighting the importance of this pathogen in Brazil. Only two of the seventeen papers are not from Brazilian groups.

Furthermore, twelve of these works were published in the last five years, reflecting the increase in studies using Sporothrix as a model due to its importance as a human pathogen. Besides, most compounds induce disruption of the cell membrane in Sporothrix cells. The MIC values show that farnesol and buparvaquone are the most promising compounds (Table 2). However, considering in vitro and in vivo approaches, the hydrazone derivative 4-bromo-N′-(3,5-dibromo-2-hydroxybenzylidene)-benzohydrazide (reported as D13 in the original study) exhibited the most interesting results, with good in vitro and in vivo activities.

5. Conclusions

The current scenario shows the emergence and re-emergence of sporotrichosis as a cosmopolitan mycosis whose etiological agents are in constant movement and associated with different transmission routes. Therefore, public policies should vary according to the epidemiological scenario, preferably using one-health strategies. Policies aimed at the human–environment interface are mandatory for areas where the sapronotic route prevails, driven by S. globosa and S. schenckii s. str. For areas where cat-transmitted sporotrichosis is emerging, policies aimed at the human–animal–environment interface are necessary (e.g., responsible animal ownership; limiting the number of cats per house; neutering campaigns; limiting cat access to the streets; cremation of dead cats). The invasive capacity of S. brasiliensis is impressive, becoming the predominant species shortly after its introduction into a new area. Such dynamics of the expansion of cat-transmitted sporotrichosis associated with S. brasiliensis occur through successive founder effect events. Therefore, the imposition of sanitary barriers preventing the free movement of sick animals is vital to tackle the geographic expansion of S. brasiliensis beyond the borders of Brazil.

In a rapidly expanding epidemic scenario, diagnostic tools need to keep up with the pace of the problem. Therefore, fast and accurate methods are important tools for laboratory diagnosis. In feline sporotrichosis, the quick Panoptic method is an efficient alternative for diagnosis given the high fungal load in the lesions, in addition to the robustness and low price. However, speciation will only be possible through the application of molecular tools. The pillar of the molecular diagnosis of sporotrichosis relies on PCR, with conventional assays that combine in vitro amplification and agarose gel electrophoresis (e.g., species-specific PCR) to multiplex reactions capable of real-time detecting mixed infections in a single tube (e.g., qPCR). Rapid diagnosis allows specific treatment, which positively impacts patients’ clinical outcomes and reduces transmission rates.

The choice of treatment for sporotrichosis depends on the triad, (i) the clinical form of the disease, (ii) the immune status of the host, and (iii) the Sporothrix species involved. The main challenge for the coming years is the sudden emergence of isolates resistant to itraconazole, the first choice to treat sporotrichosis. The good news is that a search in the Cortellis Drug Discovery Intelligence database revealed 17 new molecules or repositionable drugs in the last ten years, highlighting the hydrazone derivatives as a promising alternative based on great in vitro and in vivo activities.

All the scenarios contemplated above are interdependent and must be considered to mitigate the advance of the major mycosis of implantation worldwide.

References 304

  1. 1.

    Ramírez-Soto M., Aguilar-Ancori E., Tirado-Sánchez A., Bonifaz A. Ecological determinants of sporotrichosis etiological agents. J. Fungi. 2018;4:95.

    Not in our library10.3390/jof4030095

  2. 2.

    Orofino-Costa R.C., Macedo P.M., Rodrigues A.M., Bernardes-Engemann A.R. Sporotrichosis: An update on epidemiology, etiopathogenesis, laboratory and clinical therapeutics. An. Bras. De Dermatol. 2017;92:606-620.

    Not in our library10.1590/abd1806-4841.2017279

  3. 3.
    Sporothrix Species Causing Outbreaks in Animals and Humans Driven by Animal–Animal Transmission · 2016
    No notice
  4. 4.

    Rodrigues A.M., Bagagli E., de Camargo Z.P., Bosco S.M.G. Sporothrix schenckii sensu stricto isolated from soil in an armadillo’s burrow. Mycopathologia. 2014;177:199-206.

    Not in our library10.1007/s11046-014-9734-8

  5. 5.
    Zoonotic Epidemic of Sporotrichosis: Cat to Human Transmission · 2017
    No notice
  6. 6.

    Bonifaz A., Vázquez-González D. Diagnosis and treatment of lymphocutaneous sporotrichosis: What are the options? Curr. Fungal Infect. Rep. 2013;7:252-259.

    Not in our library10.1007/s12281-013-0140-3

  7. 7.

    Kauffman C.A., Bustamante B., Chapman S.W., Pappas P.G. Clinical practice guidelines for the management of sporotrichosis: 2007 update by the Infectious Diseases Society of America. Clin. Infect. Dis. 2007;45:1255-1265.

    Not in our library10.1086/522765

  8. 8.

    Kauffman C.A., Hajjeh R., Chapman S.W., Group M.S. Practice guidelines for the management of patients with sporotrichosis. Clin. Infect. Dis. 2000;30:684-687.

    Not in our library10.1086/313751

  9. 9.

    Aung A.K., Teh B.M., McGrath C., Thompson P.J. Pulmonary sporotrichosis: Case series and systematic analysis of literature on clinico-radiological patterns and management outcomes. Med. Mycol. 2013;51:534-544.

    Not in our library10.3109/13693786.2012.751643

  10. 10.

    Gremião I.D., Menezes R.C., Schubach T.M., Figueiredo A.B., Cavalcanti M.C., Pereira S.A. Feline sporotrichosis: Epidemiological and clinical aspects. Med. Mycol. 2015;53:15-21.

    Not in our library10.1093/mmy/myu061

  11. 11.

    Pereira S.A., Gremião I.D.F., Menezes R.C., Zeppone Carlos I. Sporotrichosis in Animals: Zoonotic Transmission. Sporotrichosis: New Developments and Future Prospects. 2015;83-102.

    Not in our library10.1007/978-3-319-11912-0_6

  12. 12.
    The epidemiological scenario of feline sporotrichosis in Rio de Janeiro, State of Rio de Janeiro, Brazil · 2014
    Not checked
  13. 13.

    Schubach A., Schubach T.M., Barros M.B., Wanke B. Cat-transmitted sporotrichosis, Rio de Janeiro, Brazil. Emerg. Infect. Dis. 2005;11:1952-1954.

    Not in our library10.3201/eid1112.040891

  14. 14.

    Gremião I.D.F., Martins da Silva da Rocha E., Montenegro H., Carneiro A.J.B., Xavier M.O., de Farias M.R., Monti F., Mansho W., de Macedo Assunção Pereira R.H., Pereira S.A., et al. Guideline for the management of feline sporotrichosis caused by Sporothrix brasiliensis and literature revision. Braz. J. Microbiol. Publ. Braz. Soc. Microbiol. 2021;52:107-124.

    Not in our library10.1007/s42770-020-00365-3

  15. 15.

    Rodrigues A.M., Della Terra P.P., Gremiao I.D., Pereira S.A., Orofino-Costa R., de Camargo Z.P. The threat of emerging and re-emerging pathogenic Sporothrix species. Mycopathologia. 2020;185:813-842.

    Not in our library10.1007/s11046-020-00425-0

  16. 16.

    Schenck B.R. On refractory subcutaneous abscesses caused by a fungus possibly related to the Sporotricha. Bull. Johns Hopkins Hosp. 1898;9:286-290.

    Not in our library

  17. 17.

    Hektoen L., Perkins C.F. Refractory subcutaneous abscesses caused by Sporothrix schenckii: A new pathogenic fungus. J. Exp. Med. 1900;5:77-89.

    Not in our library10.1084/jem.5.1.77

  18. 18.

    Marimon R., Gené J., Cano J., Trilles L., Dos Santos Lazéra M., Guarro J. Molecular phylogeny of Sporothrix schenckii. J. Clin. Microbiol. 2006;44:3251-3256.

    Not in our library10.1128/jcm.00081-06

  19. 19.

    de Beer Z.W., Duong T.A., Wingfield M.J. The divorce of Sporothrix and Ophiostoma: Solution to a problematic relationship. Stud. Mycol. 2016;83:165-191.

    Not in our library10.1016/j.simyco.2016.07.001

  20. 20.

    Rodrigues A.M., Cruz Choappa R., Fernandes G.F., De Hoog G.S., Camargo Z.P. Sporothrix chilensis sp. nov. (Ascomycota: Ophiostomatales), a soil-borne agent of human sporotrichosis with mild-pathogenic potential to mammals. Fungal Biol. 2016;120:246-264.

    Not in our library10.1016/j.funbio.2015.05.006

  21. 21.

    Sil A., Andrianopoulos A. Thermally dimorphic human fungal pathogens—Polyphyletic pathogens with a convergent pathogenicity trait. Cold Spring Harb. Perspect. Med. 2014;5:a019794.

    Not in our library10.1101/cshperspect.a019794

  22. 22.

    Fernandes G.F., dos Santos P.O., Amaral C.C., Sasaki A.A., Godoy-Martinez P., Camargo Z.P.d. Characteristics of 151 Brazilian Sporothrix schenckii isolates from 5 different geographic regions of Brazil: A forgotten and re-emergent pathogen. Open Mycol. J. 2009;3:48-58.

    Not in our library10.2174/1874437000903010048

  23. 23.

    Fernandes G.F., dos Santos P.O., Rodrigues A.M., Sasaki A.A., Burger E., de Camargo Z.P. Characterization of virulence profile, protein secretion and immunogenicity of different Sporothrix schenckii sensu stricto isolates compared with S. globosa and S. brasiliensis species. Virulence. 2013;4:241-249.

    Not in our library10.4161/viru.23112

  24. 24.

    Della Terra P.P., Rodrigues A.M., Fernandes G.F., Nishikaku A.S., Burger E., de Camargo Z.P. Exploring virulence and immunogenicity in the emerging pathogen Sporothrix brasiliensis. PLoS Negl. Trop. Dis. 2017;11:e0005903.

    Not in our library10.1371/journal.pntd.0005903

  25. 25.

    Almeida-Paes R., de Oliveira L.C., Oliveira M.M.E., Gutierrez-Galhardo M.C., Nosanchuk J.D., Zancopé Oliveira R.M. Phenotypic characteristics associated with virulence of clinical isolates from the Sporothrix complex. BioMed Res. Int. 2015;2015:1-10.

    Not in our library10.1155/2015/212308

  26. 26.

    Arrillaga-Moncrieff I., Capilla J., Mayayo E., Marimon R., Mariné M., Gené J., Cano J., Guarro J. Different virulence levels of the species of Sporothrix in a murine model. Clin. Microbiol. Infect. 2009;15:651-655.

    Not in our library10.1111/j.1469-0691.2009.02824.x

  27. 27.

    de Macedo P.M., Sztajnbok D.C., Camargo Z.P., Rodrigues A.M., Lopes-Bezerra L.M., Bernardes-Engemann A.R., Orofino-Costa R. Dacryocystitis due to Sporothrix brasiliensis: A case report of a successful clinical and serological outcome with low-dose potassium iodide treatment and oculoplastic surgery. Br. J. Dermatol. 2015;172:1116-1119.

    Not in our library10.1111/bjd.13378

  28. 28.

    Silva-Vergara M.L., de Camargo Z.P., Silva P.F., Abdalla M.R., Sgarbieri R.N., Rodrigues A.M., dos Santos K.C., Barata C.H., Ferreira-Paim K. Disseminated Sporothrix brasiliensis infection with endocardial and ocular involvement in an HIV-infected patient. Am. J. Trop. Med. Hyg. 2012;86:477-480.

    Not in our library10.4269/ajtmh.2012.11-0441

  29. 29.
    Sporotrichosis in Rio de Janeiro, Brazil: Sporothrix brasiliensis Is Associated with Atypical Clinical Presentations · 2014
    No notice
  30. 30.

    Nepomuceno Araujo M., Nihei C.H., Rodrigues A.M., Higashino H., Ponzio V., Campos Pignatari A.C., Barcellos M.A., Braga O., Duayer I.F. Case report: Invasive sinusitis due to Sporothrix brasiliensis in a renal transplant recipient. Am. J. Trop. Med. Hyg. 2021;105:1218-1221.

    Not in our library10.4269/ajtmh.20-1602

  31. 31.

    do Monte Alves M., Pipolo Milan E., da Silva-Rocha W.P., Soares de Sena da Costa A., Araujo Maciel B., Cavalcante Vale P.H., de Albuquerque P.R., Lopes Lima S., Salles de Azevedo Melo A., Messias Rodrigues A., et al. Fatal pulmonary sporotrichosis caused by Sporothrix brasiliensis in Northeast Brazil. PLoS Negl. Trop. Dis. 2020;14:e0008141.

    Not in our library10.1371/journal.pntd.0008141

  32. 32.

    Barros M.B., de Almeida Paes R., Schubach A.O. Sporothrix schenckii and sporotrichosis. Clin. Microbiol. Rev. 2011;24:633-654.

    Not in our library10.1128/cmr.00007-11

  33. 33.

    Dangerfield L.F., Gear J. Sporotrichosis among miners on the Witwatersrand gold mines. S.A. Med. J. 1941;15:128-131.

    Not in our library

  34. 34.

    Pijper A., Pullinger B.D. An outbreak of sporotrichosis among South African native miners. Lancet. 1927;210:914-916.

    Not in our library10.1016/s0140-6736(01)35176-0

  35. 35.

    Brown R., Bowen J.W., Weintroub D., Cluver E.H., Buchanan G., Simson F.W., Lurie H.I., Du Toit C.J., Golberg L., Goedvolk C.J., et al. Sporotrichosis infection on mines of the Witwatersrand. Proceedings of the Transvaal Mine Medical Officer’s Association. 1-67.

    Not in our library

  36. 36.

    Govender N.P., Maphanga T.G., Zulu T.G., Patel J., Walaza S., Jacobs C., Ebonwu J.I., Ntuli S., Naicker S.D., Thomas J. An outbreak of lymphocutaneous sporotrichosis among mine-workers in South Africa. PLoS Negl. Trop. Dis. 2015;9:e0004096.

    Not in our library10.1371/journal.pntd.0004096

  37. 37.

    Vismer H.F., Hull P.R. Prevalence, epidemiology and geographical distribution of Sporothrix schenckii infections in Gauteng, South Africa. Mycopathologia. 1997;137:137-143.

    Not in our library10.1023/a:1006830131173

  38. 38.

    Nenoff P., Reinel D., Kruger C., Grob H., Mugisha P., Suss A., Mayser P. Tropical and travel-related dermatomycoses: Part 2: Cutaneous infections due to yeasts, moulds, and dimorphic fungi. Der Hautarzt Z. Fur. Dermatol. Venerol. Und Verwandte Geb. 2015;66:522-532.

    Not in our library10.1007/s00105-015-3635-8

  39. 39.

    Callens S.F., Kitetele F., Lukun P., Lelo P., Van Rie A., Behets F., Colebunders R. Pulmonary Sporothrix schenckii infection in a HIV positive child. J. Trop. Pediatrics. 2006;52:144-146.

    Not in our library10.1093/tropej/fmi101

  40. 40.

    Ponnighaus M., Grosser S., Baum H.P., Mischke D., Kowalzick L. Sporotrichosis as the cause of a leg ulcer. Der Hautarzt; Z. Fur Dermatol. Venerol. Und Verwandte Geb. 2003;54:64-66.

    Not in our library10.1007/s00105-002-0400-6

  41. 41.

    Findlay G. Sporotrichosis research in the Transvaal-how it began 60 years ago. S. Afr. Med. J. Suid-Afrik. Tydskr. Vir Geneeskd. 1985;68:117-118.

    Not in our library

  42. 42.

    Dalis J.S., Kazeem H.M., Kwaga J.K., Kwanashie C.N. Severe generalized skin lesions due to mixed infection with Sporothrix schenkii and Dermatophilus congolensis in a bull from Jos, Nigeria. Vet. Microbiol. 2014;172:475-478.

    Not in our library10.1016/j.vetmic.2014.05.014

  43. 43.

    Rasamoelina T., Maubon D., Raharolahy O., Razanakoto H., Rakotozandrindrainya N., Rakotomalala F.A., Bailly S., Sendrasoa F., Ranaivo I., Andrianarison M. Sporotrichosis in the Highlands of Madagascar, 2013–2017. Emerg. Infect. Dis. 2019;25:1893-1902.

    Not in our library10.3201/eid2510.190700

  44. 44.

    Ross M.D., Gelfand M. Deep fungal infections in Rhodesia—A 10-year survey of histological material. Part I Cent. Afr. J. Med. 1978;24:208-212.

    Not in our library

  45. 45.

    Jacyk W.K., Lawande R.V., Tulpule S.S. Deep mycoses in West Africa: A report of 13 cases and review of the Nigerian literature. J. Natl. Med. Assoc. 1981;73:251-256.

    Not in our library

  46. 46.

    Gumaa S.A. Sporotrichosis in Sudan. Trans. R. Soc. Trop. Med. Hyg. 1978;72:637-640.

    Not in our library10.1016/0035-9203(78)90020-2

  47. 47.

    Chakrabarti A., Bonifaz A., Gutierrez-Galhardo M.C., Mochizuki T., Li S. Global epidemiology of sporotrichosis. Med. Mycol. 2015;53:3-14.

    Not in our library10.1093/mmy/myu062

  48. 48.

    Sharma N.L., Mehta K.I., Mahajan V.K., Kanga A.K., Sharma V.C., Tegta G.R. Cutaneous sporotrichosis of face: Polymorphism and reactivation after intralesional triamcinolone. Indian J. Dermatol. Venereol. Leprol. 2007;73:188-190.

    Not in our library10.4103/0378-6323.32745

  49. 49.

    Mehta K.I.S., Sharma N.L., Kanga A.K., Mahajan V.K., Ranjan N. Isolation of Sporothrix schenckii from the environmental sources of cutaneous sporotrichosis patients in Himachal Pradesh, India: Results of a pilot study. Mycoses. 2007;50:496-501.

    Not in our library10.1111/j.1439-0507.2007.01411.x

  50. 50.
    Sporotrichosis in sub-himalayan India. · 2012
    Not checked
  51. 51.

    Rudramurthy S.M., Shankarnarayan S.A., Hemashetter B.M., Verma S., Chauhan S., Nath R., Savio J., Capoor M., Kaur H., Ghosh A.K., et al. Phenotypic and molecular characterisation of Sporothrix globosa of diverse origin from India. Braz. J. Microbiol. Publ. Braz. Soc. Microbiol. 2021;52:91-100.

    Not in our library10.1007/s42770-020-00346-6

  52. 52.

    Fukushiro R. Epidemiology and ecology of sporotrichosis in Japan. Zent. Bakteriol. Mikrobiol. Hyg. A. 1984;257:228-233.

    Not in our library10.1016/s0174-3031(84)80076-1

  53. 53.

    Ishizaki H., Kawasaki M. Molecular epidemiology of Sporothrix schenckii. Nihon Ishinkin Gakkai Zasshi. 2000;41:245-249.

    Not in our library10.3314/jjmm.41.245

  54. 54.

    Takeda Y., Kawasaki M., Ishizaki H. Phylogeny and molecular epidemiology of Sporothrix schenckii in Japan. Mycopathologia. 1991;116:9-14.

    Not in our library10.1007/bf00436084

  55. 55.

    Suzuki K., Kawasaki M., Ishizaki H. Analysis of restriction profiles of mitochondrial DNA from Sporothrix schenckii and related fungi. Mycopathologia. 1988;103:147-151.

    Not in our library10.1007/bf00436813

  56. 56.

    Ishizaki H., Kawasaki M., Aoki M., Wu S., Lin J., Kim J.A., Won Y.H., Calvo C.R. Mitochondrial DNA analysis of Sporothrix schenckii from China, Korea and Spain. Nihon Ishinkin Gakkai Zasshi. 2004;45:23-25.

    Not in our library10.3314/jjmm.45.23

  57. 57.

    Ishizaki H., Kawasaki M., Aoki M., Vismer H., Muir D. Mitochondrial DNA analysis of Sporothrix schenckii in South Africa and Australia. Med. Mycol. 2000;38:433-436.

    Not in our library10.1080/mmy.38.6.433.436

  58. 58.

    Ishizaki H., Kawasaki M., Aoki M., Matsumoto T., Padhye A.A., Mendoza M., Negroni R. Mitochondrial DNA analysis of Sporothrix schenckii in North and South America. Mycopathologia. 1998;142:115-118.

    Not in our library10.1023/a:1006952702947

  59. 59.

    Mochizuki H., Anzawa K., Mochizuki T. Genotyping of intraspecies polymorphisms of Sporothrix globosa using partial sequence of mitochondrial DNA. J. Derm. 2022;49:263-271.

    Not in our library10.1111/1346-8138.16235

  60. 60.

    Kawasaki M., Anzawa K., Mochizuki T., Ishizaki H. New strain typing method with Sporothrix schenckii using mitochondrial DNA and polymerase chain reaction restriction fragment length polymorphism (PCR–RFLP) technique. J. Derm. 2012;39:362-365.

    Not in our library10.1111/j.1346-8138.2011.01379.x

  61. 61.

    Moussa T.A., Kadasa N.M., Al Zahrani H.S., Ahmed S.A., Feng P., Gerrits van den Ende A.H., Zhang Y., Kano R., Li F., Li S., et al. Origin and distribution of Sporothrix globosa causing sapronoses in Asia. J. Med. Microbiol. 2017;66:560-569.

    Not in our library10.1099/jmm.0.000451

  62. 62.

    Liu T.-T., Zhang K., Zhou X. Molecular identification of Sporothrix clinical isolates in China. J. Zhejiang Univ. Sci. B. 2014;15:100-108.

    Not in our library10.1631/jzus.b1300136

  63. 63.

    Yu X., Wan Z., Zhang Z., Li F., Li R., Liu X. Phenotypic and molecular identification of Sporothrix isolates of clinical origin in Northeast China. Mycopathologia. 2013;176:67-74.

    Not in our library10.1007/s11046-013-9668-6

  64. 64.

    Lv S., Hu X., Liu Z., Lin Y., Wu H., Li F. Clinical epidemiology of sporotrichosis in Jilin province, China (1990-2019): A series of 4969 cases. Infect. Drug Resist. 2022;15:1753-1765.

    Not in our library10.2147/idr.s354380

  65. 65.

    Song Y., Li S.S., Zhong S.X., Liu Y.Y., Yao L., Huo S.S. Report of 457 sporotrichosis cases from Jilin province, northeast China, a serious endemic region. J. Eur. Acad. Derm. Venereol. 2013;27:313-318.

    Not in our library10.1111/j.1468-3083.2011.04389.x

  66. 66.

    Yao L., Song Y., Cui Y., Zhou J.F., Zhong S.X., Zhao D.Y., Li S.S. Pediatric sporotrichosis in Jilin province of China (2010-2016): A retrospective study of 704 cases. J. Pediatric Infect. Dis. Soc. 2019;9:342-348.

    Not in our library10.1093/jpids/piz052

  67. 67.

    Yao L., Song Y., Zhou J.F., Cui Y., Li S.S. Epidemiological and clinical comparisons of pediatric and adult sporotrichosis in Jilin Province, China. Mycoses. 2020;63:308-313.

    Not in our library10.1111/myc.13045

  68. 68.

    Zhang Y., Hagen F., Stielow B., Rodrigues A.M., Samerpitak K., Zhou X., Feng P., Yang L., Chen M., Deng S., et al. Phylogeography and evolutionary patterns in Sporothrix spanning more than 14,000 human and animal case reports. Persoonia. 2015;35:1-20.

    Not in our library10.3767/003158515x687416

  69. 69.

    Zamri-Saad M., Salmiyah T.S., Jasni S., Cheng B.Y., Basri K. Feline sporotrichosis: An increasingly important zoonotic disease in Malaysia. Vet. Rec. 1990;127:480.

    Not in our library

  70. 70.

    Tang M.M., Tang J.J., Gill P., Chang C.C., Baba R. Cutaneous sporotrichosis: A six-year review of 19 cases in a tertiary referral center in Malaysia. Int. J. Derm. 2012;51:702-708.

    Not in our library10.1111/j.1365-4632.2011.05229.x

  71. 71.

    Kano R., Okubo M., Siew H.H., Kamata H., Hasegawa A. Molecular typing of Sporothrix schenckii isolates from cats in Malaysia. Mycoses. 2015;58:220-224.

    Not in our library10.1111/myc.12302

  72. 72.

    Beurmann L., Ramond L. Abcès sous-cutanés multiples d’origine mycosique. Ann. Derm. Syph. 1903;4:678-685.

    Not in our library

  73. 73.

    Matruchot L. Sur un nouveau groupe de champignons pathogènes, agents des sporotrichoses. Comptes Rendus De L’Académie De Sci. 1910;150:543-545.

    Not in our library

  74. 74.

    Beurmann L., Gougerot H. Les Sporotrichose. 1912.

    Not in our library

  75. 75.

    Romeo O., Scordino F., Criseo G. New insight into molecular phylogeny and epidemiology of Sporothrix schenckii species complex based on calmodulin-encoding gene analysis of Italian isolates. Mycopathologia. 2011;172:179-186.

    Not in our library10.1007/s11046-011-9420-z

  76. 76.

    Criseo G., Romeo O. Ribosomal DNA sequencing and phylogenetic analysis of environmental Sporothrix schenckii strains: Comparison with clinical isolates. Mycopathologia. 2010;169:351-358.

    Not in our library10.1007/s11046-010-9274-9

  77. 77.

    Criseo G., Malara G., Romeo O., Puglisi Guerra A. Lymphocutaneous sporotrichosis in an immunocompetent patient: A case report from extreme southern Italy. Mycopathologia. 2008;166:159-162.

    Not in our library10.1007/s11046-008-9121-4

  78. 78.

    Marimon R., Cano J., Gené J., Sutton D.A., Kawasaki M., Guarro J. Sporothrix brasiliensis, S. globosa, and S. mexicana, three new Sporothrix species of clinical interest. J. Clin. Microbiol. 2007;45:3198-3206.

    Not in our library10.1128/jcm.00808-07

  79. 79.

    Madrid H., Cano J., Gene J., Bonifaz A., Toriello C., Guarro J. Sporothrix globosa, a pathogenic fungus with widespread geographical distribution. Rev. Iberoam. De Micol. 2009;26:218-222.

    Not in our library10.1016/j.riam.2009.02.005

  80. 80.

    Rachman R., Ligaj M., Chinthapalli S., Serafino Wani R. Zoonotic acquisition of cutaneous Sporothrix brasiliensis infection in the UK. BMJ Case Rep. 2022;15:e248418.

    Not in our library10.1136/bcr-2021-248418

  81. 81.

    McGuinness S.L., Boyd R., Kidd S., McLeod C., Krause V.L., Ralph A.P. Epidemiological investigation of an outbreak of cutaneous sporotrichosis, Northern Territory, Australia. BMC Infect. Dis. 2016;16:16.

    Not in our library10.1186/s12879-016-1338-0

  82. 82.

    New D., Beukers A.G., Kidd S.E., Merritt A.J., Weeks K., van Hal S.J., Arthur I. Identification of multiple species and subpopulations among Australian clinical Sporothrix isolates using whole genome sequencing. Med. Mycol. 2019;57:905-908.

    Not in our library10.1093/mmy/myy126

  83. 83.

    Schauer A., Campbell A.J., Arthur I., Blyth C.C., Bowen A.C. Spotting sporotrichosis skin infection: The first Australian paediatric case series. J. Paediatr. Child Health. 2020;56:408-410.

    Not in our library10.1111/jpc.14639

  84. 84.

    Mackay B., Menrath V., Ridley M., Kelly W. Sporotrichosis in a cat. Aust. Vet Pr. 1986;16:3-5.

    Not in our library

  85. 85.

    Thomson J., Trott D.J., Malik R., Galgut B., McAllister M.M., Nimmo J., Renton D., Kidd S.E. An atypical cause of sporotrichosis in a cat. Med. Mycol. Case Rep. 2019;23:72-76.

    Not in our library10.1016/j.mmcr.2019.01.004

  86. 86.

    Dixon D.M., Salkin I.F., Duncan R.A., Hurd N.J., Haines J.H., Kemna M.E., Coles F.B. Isolation and characterization of Sporothrix schenckii from clinical and environmental sources associated with the largest U.S. epidemic of sporotrichosis. J. Clin. Microbiol. 1991;29:1106-1113.

    Not in our library10.1128/jcm.29.6.1106-1113.1991

  87. 87.

    Coles F.B., Schuchat A., Hibbs J.R., Kondracki S.F., Salkin I.F., Dixon D.M., Chang H.G., Duncan R.A., Hurd N.J., Morse D.L. A multistate outbreak of sporotrichosis associated with Sphagnum moss. Am. J. Epidemiol. 1992;136:475-487.

    Not in our library10.1093/oxfordjournals.aje.a116521

  88. 88.
    Sporotrichosis-Associated Hospitalizations, United States, 2000–2013 · 2016
    Not checked
  89. 89.

    Queiroz-Telles F., Fahal A.H., Falci D.R., Caceres D.H., Chiller T., Pasqualotto A.C. Neglected endemic mycoses. Lancet Infect. Dis. 2017;17:e367-e377.

    Not in our library10.1016/s1473-3099(17)30306-7

  90. 90.

    Hernández-Castro R., Pinto-Almazán R., Arenas R., Sánchez-Cárdenas C.D., Espinosa-Hernández V.M., Sierra-Maeda K.Y., Conde-Cuevas E., Juárez-Durán E.R., Xicohtencatl-Cortes J., Carrillo-Casas E.M., et al. Epidemiology of clinical sporotrichosis in the Americas in the last ten years. J. Fungi. 2022;8:588.

    Not in our library10.3390/jof8060588

  91. 91.

    Rodrigues A.M., de Hoog G.S., Zhang Y., Camargo Z.P. Emerging sporotrichosis is driven by clonal and recombinant Sporothrix species. Emerg. Microbes Infect. 2014;3:e32.

    Not in our library10.1038/emi.2014.33

  92. 92.

    Florez-Munoz S.V., Alzate J.F., Mesa-Arango A.C. Molecular identification and antifungal susceptibility of clinical isolates of Sporothrix schenckii complex in Medellin, Colombia. Mycopathologia. 2019;184:53-63.

    Not in our library10.1007/s11046-018-0310-5

  93. 93.

    Ramirez Soto M.C. Sporotrichosis: The Story of an Endemic Region in Peru over 28 Years (1985 to 2012). PLoS ONE. 2015;10:e0127924.

    Not in our library10.1371/journal.pone.0127924

  94. 94.

    Pappas P.G., Tellez I., Deep A.E., Nolasco D., Holgado W., Bustamante B. Sporotrichosis in Peru: Description of an area of hyperendemicity. Clin. Infect Dis. 2000;30:65-70.

    Not in our library10.1086/313607

  95. 95.

    Camacho E., León-Navarro I., Rodríguez-Brito S., Mendoza M., Niño-Vega G.A. Molecular epidemiology of human sporotrichosis in Venezuela reveals high frequency of Sporothrix globosa. BMC Infect Dis. 2015;15:94.

    Not in our library10.1186/s12879-015-0839-6

  96. 96.
    Molecular Diagnosis of Pathogenic Sporothrix Species · 2015
    No notice
  97. 97.

    Rodrigues A.M., de Hoog G.S., de Cassia Pires D., Brilhante R.S.N., da Costa Sidrim J.J., Gadelha M.F., Colombo A.L., de Camargo Z.P. Genetic diversity and antifungal susceptibility profiles in causative agents of sporotrichosis. BMC Infect. Dis. 2014;14:219.

    Not in our library10.1186/1471-2334-14-219

  98. 98.

    Rodrigues A.M., de Hoog S., de Camargo Z.P. Emergence of pathogenicity in the Sporothrix schenckii complex. Med. Mycol. 2013;51:405-412.

    Not in our library10.3109/13693786.2012.719648

  99. 99.
    Phylogenetic Analysis Reveals a High Prevalence of Sporothrix brasiliensis in Feline Sporotrichosis Outbreaks · 2013
    No notice
  100. 100.

    Falcão E.M.M., de Lima Filho J.B., Campos D.P., Valle A.C.F.d., Bastos F.I., Gutierrez-Galhardo M.C., Freitas D.F.S. [Hospitalizations and deaths related to sporotrichosis in Brazil (1992–2015)]. Cad. De Saude Publica. 2019;35:e00109218.

    Not in our library10.1590/0102-311x00109218

  101. 101.

    de Carvalho J.A., Beale M.A., Hagen F., Fisher M.C., Kano R., Bonifaz A., Toriello C., Negroni R., Rego R.S.M., Gremiao I.D.F., et al. Trends in the molecular epidemiology and population genetics of emerging Sporothrix species. Stud. Mycol. 2021;100:100129.

    Not in our library10.1016/j.simyco.2021.100129

  102. 102.

    Araujo A.K.L., de Santana Leal C.A. Feline sporotrichosis in the municipality of Bezerros, Agreste Pernambucano: Case report. Pubvet. 2016;10:795-872.

    Not in our library10.22256/pubvet.v10n11.816-820

  103. 103.

    Nunes G.D.L., dos Santos Carneiro R., Filgueira K.D., Filgueira F.G.F., Fernandes T.H.T. Feline sporotrichosis in Itaporanga municipality, Paraíba state, Brazil: Case report. Arq. De Ciências Veterinárias E Zool. Da UNIPAR. 2011;14.

    Not in our library

  104. 104.

    Filgueira K.D. Sporotrichosis in the canine species: A case report on city of Mossoro, RN. Cienc. Anim. Bras. 2009;10:673-677.

    Not in our library

  105. 105.

    de Oliveira Bento A., de Sena Costa A.S., Lima S.L., do Monte Alves M., de Azevedo Melo A.S., Rodrigues A.M., da Silva-Rocha W.P., Milan E.P., Chaves G.M. The spread of cat-transmitted sporotrichosis due to Sporothrix brasiliensis in Brazil towards the Northeast region. PLoS Negl. Trop. Dis. 2021;15:e0009693.

    Not in our library10.1371/journal.pntd.0009693

  106. 106.

    Schubach T.M., Schubach A., Okamoto T., Barros M.B., Figueiredo F.B., Cuzzi T., Fialho-Monteiro P.C., Reis R.S., Perez M.A., Wanke B. Evaluation of an epidemic of sporotrichosis in cats: 347 cases (1998–2001). J. Am. Vet. Med. Assoc. 2004;224:1623-1629.

    Not in our library10.2460/javma.2004.224.1623

  107. 107.

    Schubach A.O., Schubach T.M., Barros M.B. Epidemic cat-transmitted sporotrichosis. N. Engl. J. Med. 2005;353:1185-1186.

    Not in our library10.1056/nejmc051680

  108. 108.

    Falcao E.M.M., Pires M.C.S., Andrade H.B., Goncalves M.L.C., Almeida-Paes R., do Valle A.C.F., Bastos F.I., Gutierrez-Galhardo M.C., Freitas D.F.S. Zoonotic sporotrichosis with greater severity in Rio de Janeiro, Brazil: 118 hospitalizations and 11 deaths in the last 2 decades in a reference institution. Med. Mycol. 2019;58:141-143.

    Not in our library10.1093/mmy/myz024

  109. 109.

    Córdoba S., Isla G., Szusz W., Vivot W., Hevia A., Davel G., Canteros C.E. Molecular identification and susceptibility profile of Sporothrix schenckii sensu lato isolated in Argentina. Mycoses. 2018;61:441-448.

    Not in our library10.1111/myc.12760

  110. 110.

    Etchecopaz A.N., Lanza N., Toscanini M.A., Devoto T.B., Pola S.J., Daneri G.L., Iovannitti C.A., Cuestas M.L. Sporotrichosis caused by Sporothrix brasiliensis in Argentina: Case report, molecular identification and in vitro susceptibility pattern to antifungal drugs. J. De Mycol. Med. 2019;30:100908.

    Not in our library10.1016/j.mycmed.2019.100908

  111. 111.

    García Duarte J.M., Wattiez Acosta V.R., Fornerón Viera P.M.L., Aldama Caballero A., Gorostiaga Matiauda G.A., Rivelli de Oddone V.B., Pereira Brunelli J.G. Sporotrichosis transmitted by domestic cat. A family case report. Rev. Del Nac. 2017;9:67-76.

    Not in our library10.18004/rdn2017.0009.02.067-076

  112. 112.

    Rios M.E., Suarez J.M.D., Moreno J., Vallee J., Moreno J.P. Zoonotic sporotrichosis related to cat contact: First case report from Panama in Central America. Cureus. 2018;10:e2906.

    Not in our library10.7759/cureus.2906

  113. 113.

    PAHO. Sporothrix brasiliensis, an Emerging Fungal Pathogen, Notable for its Zoonotic Transmission and Epidemic Potential for Human and Animal Health in the Americas.

    Not in our library

  114. 114.

    Montenegro H., Rodrigues A.M., Galvão Dias M.A., da Silva E.A., Bernardi F., Camargo Z.P. Feline sporotrichosis due to Sporothrix brasiliensis: An emerging animal infection in São Paulo, Brazil. BMC Vet Res. 2014;10:269.

    Not in our library10.1186/s12917-014-0269-5

  115. 115.

    Zhou X., Rodrigues A.M., Feng P., Hoog G.S. Global ITS diversity in the Sporothrix schenckii complex. Fungal Divers. 2014;66:153-165.

    Not in our library10.1007/s13225-013-0220-2

  116. 116.

    Rediguieri B.C., da Cruz Bahiense I., de Carvalho J.A., Leite G.R., Falqueto A., Rodrigues A.M., Gonçalves S.S. Clinical, epidemiological, and epizootic features of Sporothrix brasiliensis in Espírito Santo, Brazil. Ecohealth. 2022;19:124-134.

    Not in our library10.1007/s10393-022-01578-8

  117. 117.

    Maschio-Lima T., Marques M.D.R., Lemes T.H., Brizzotti-Mazuchi N.S., Caetano M.H., de Almeida B.G., Bianco L.M., Monteiro R.C., Rodrigues A.M., de Camargo Z.P., et al. Clinical and epidemiological aspects of feline sporotrichosis caused by Sporothrix brasiliensis and in vitro antifungal susceptibility. Vet. Res. Commun. 2021;45:171-179.

    Not in our library10.1007/s11259-021-09795-2

  118. 118.

    da Cruz Bahiense Rocha I., Terra P.P.D., Cardoso de Oliveira R., Lubianca Zanotti R., Falqueto A., de Camargo Z.P., Rodrigues A.M., Goncalves S.S. Molecular-based assessment of diversity and population structure of Sporothrix spp. clinical isolates from Espirito Santo-Brazil. Mycoses. 2021;64:420-427.

    Not in our library10.1111/myc.13230

  119. 119.

    Macêdo-Sales P.A., Souza L.O.P., Della-Terra P.P., Lozoya-Pérez N.E., Machado R.L.D., Rocha E.M.d.S.d., Lopes-Bezerra L.M., Guimarães A.J., Rodrigues A.M., Mora-Montes H.M., et al. Coinfection of domestic felines by distinct Sporothrix brasiliensis in the Brazilian sporotrichosis hyperendemic area. Fungal Genet. Biol. 2020;140:103397.

    Not in our library10.1016/j.fgb.2020.103397

  120. 120.

    Macêdo-Sales P.A., Souto S.R.L.S., Destefani C.A., Lucena R.P., Machado R.L.D., Pinto M.R., Rodrigues A.M., Lopes-Bezerra L.M., Rocha E.M.S., Baptista A.R.S. Domestic feline contribution in the transmission of Sporothrix in Rio de Janeiro State, Brazil: A comparison between infected and non-infected populations. BMC Vet. Res. 2018;14:19.

    Not in our library10.1186/s12917-018-1340-4

  121. 121.

    Teixeira M.d.M., Rodrigues A.M., Tsui C.K.M., de Almeida L.G.P., Van Diepeningen A.D., Gerrits van den Ende B., Fernandes G.F., Kano R., Hamelin R.C., Lopes-Bezerra L.M., et al. Asexual propagation of a virulent clone complex in human and feline outbreak of sporotrichosis. Eukaryot Cell. 2015;14:158-169.

    Not in our library10.1128/ec.00153-14

  122. 122.

    Rodrigues A.M., Fernandes G.F., Araujo L.M., Della Terra P.P., Dos Santos P.O., Pereira S.A., Schubach T.M., Burger E., Lopes-Bezerra L.M., de Camargo Z.P. Proteomics-based characterization of the humoral immune response in sporotrichosis: Toward discovery of potential diagnostic and vaccine antigens. PLoS Negl. Trop. Dis. 2015;9:e0004016.

    Not in our library10.1371/journal.pntd.0004016

  123. 123.

    Freitas D.C., Migliano M.F., Zani Neto L. Sporotrichosis. Observation of spontaneous case in domestic cat (Felis catus). Rev. Fac. Med. Vet. Univ. Sao Paulo. 1956;5:601-604.

    Not in our library10.11606/issn.2318-5066.v5i4p601-604

  124. 124.

    Freitas D.C., Moreno G., Saliba A.M., Botino J.Á., Mós E.M. Sporotrichosis in dogs and cats. Rev. Fac. Med. Vet Univ. Sao Paulo. 1965;7:381-387.

    Not in our library10.11606/issn.2318-5066.v7i2p381-388

  125. 125.

    Almeida F., Sampaio S.A.P., Lacaz C.S., Fernandes J.C. Statistical data on sporotrichosis. Analysis of 344 cases. An. Bras. De Dermatol. 1955;30:9-12.

    Not in our library

  126. 126.

    Lacaz C.S., Porto E., Martins J.E.C., Heins-Vaccari E.M., de Melo N.T. Tratado de Micologia Médica. 2002;1104.

    Not in our library

  127. 127.

    Marques S.A., Franco S.R., de Camargo R.M., Dias L.D., Haddad Junior V., Fabris V.E. Sporotrichosis of the domestic cat (Felis catus): Human transmission. Rev. Do Inst. De Med. Trop. De Sao Paulo. 1993;35:327-330.

    Not in our library

  128. 128.

    Baroni F., Campos S., Direito G. Sporotrichosis in a cat (a case description). Rev. Bras. Med. Vet. 1998;20:25-27.

    Not in our library

  129. 129.

    Barros M.B.d.L., Schubach T.P., Coll J.O., Gremião I.D., Wanke B., Schubach A. Sporotrichosis: Development and challenges of an epidemic. Rev. Panam. Salud Publica. 2010;27:455-460.

    Not in our library10.1590/s1020-49892010000600007

  130. 130.
    Geographic Expansion of Sporotrichosis, Brazil · 2020
    No notice
  131. 131.

    Larsson C.E., Goncalves Mde A., Araujo V.C., Dagli M.L., Correa B., Fava Neto C. Feline sporotrichosis: Clinical and zoonotic aspects. Rev. Do Inst. De Med. Trop. De Sao Paulo. 1989;31:351-358.

    Not in our library10.1590/s0036-46651989000500010

  132. 132.

    Borges T.S., Rossi C.N., Fedullo J.D., Taborda C.P., Larsson C.E. Isolation of Sporothrix schenckii from the claws of domestic cats (indoor and outdoor) and in captivity in Sao Paulo (Brazil). Mycopathologia. 2013;176:129-137.

    Not in our library10.1007/s11046-013-9658-8

  133. 133.

    Silva C.E., Valeriano C.A.T., Ferraz C.E., Neves R.P., Oliveira M.M.E., Silva J.C.A.L., Magalhães V., Lima-Neto R.G. Epidemiological features and geographical expansion of sporotrichosis in the state of Pernambuco, northeastern Brazil. Future Microbiol. 2021;16:1371-1379.

    Not in our library10.2217/fmb-2021-0142

  134. 134.

    Larsson C.E. Sporotrichosis. Braz. J. Vet. Res. Anim. Sci. 2011;48:250-259.

    Not in our library10.11606/s1413-95962011000300010

  135. 135.

    Almeida F.P. Micologia Médica: Estudo das Micoses Humanas e de Seus Cogumelos. 1939;710.

    Not in our library

  136. 136.

    Fernandes C.G.N., Moura S.T.d., Dantas A.F.M., Blatt M.C.S. Feline sporotrichosis: Clinical epidemiological aspects: Case reports (Cuiabá, Mato Grosso, Brasil). MEDVEP. Rev. Cient. Med. Vet. 2004;2:39-43.

    Not in our library

  137. 137.

    SES-MS. Sporotrichosis Technical Note—Nº 1/2021-GTZ/CEVE/DGVS/SES.

    Not in our library

  138. 138.

    CRMV-SE. Technical Note No. 01/2021.

    Not in our library

  139. 139.

    SES-AM. Joint Technical Note—Nº 006/2021—GEVEP/DEVAE/DAP/DRA/SUBGS.

    Not in our library

  140. 140.

    COVISA. Technical Note 09: DVE/DVZ/COVISA/2020—Surveillance and Clinical Management of Human Sporotrichosis in the Municipality of São Paulo.

    Not in our library

  141. 141.

    Bison I. Feline Sporotrichosis: Literature Review. Bachelor’s Thesis. 2019.

    Not in our library

  142. 142.

    Boechat J.S., Oliveira M.M.E., Almeida-Paes R., Gremiao I.D.F., Machado A.C.S., Oliveira R.V.C., Figueiredo A.B.F., Rabello V.B.S., Silva K.B.L., Zancope-Oliveira R.M., et al. Feline sporotrichosis: Associations between clinical-epidemiological profiles and phenotypic-genotypic characteristics of the etiological agents in the Rio de Janeiro epizootic area. Mem. Do Inst. Oswaldo Cruz. 2018;113:185-196.

    Not in our library10.1590/0074-02760170407

  143. 143.

    de Souza E.W., Borba C.M., Pereira S.A., Gremiao I.D.F., Langohr I.M., Oliveira M.M.E., de Oliveira R.V.C., da Cunha C.R., Zancope-Oliveira R.M., de Miranda L.H.M., et al. Clinical features, fungal load, coinfections, histological skin changes, and itraconazole treatment response of cats with sporotrichosis caused by Sporothrix brasiliensis. Sci. Rep. 2018;8:9074.

    Not in our library10.1038/s41598-018-27447-5

  144. 144.

    de Araujo M.L., Rodrigues A.M., Fernandes G.F., de Camargo Z.P., de Hoog G.S. Human sporotrichosis beyond the epidemic front reveals classical transmission types in Espírito Santo, Brazil. Mycoses. 2015;58:485-490.

    Not in our library10.1111/myc.12346

  145. 145.

    Colodel M.M., Jark P.C., Ramos C.J.R., Martins V.M.V., Schneider A.F., Pilati C. Feline cutaneous sporotrichosis in the state of Santa Catarina: Case reports. Vet. Foco. 2009;7:18-27.

    Not in our library

  146. 146.

    Cordeiro F.N., Bruno C.B., Paula C.D., Motta Jde O. Familial occurrence of zoonotic sporotrichosis. An. Bras. De Dermatol. 2011;86:S121-S124.

    Not in our library10.1590/s0365-05962011000700032

  147. 147.

    Silva G.M., Howes J.C.F., Leal C.A.S., Mesquita E.P., Pedrosa C.M., Oliveira A.A.F., Silva L.B.G., Mota R.A. Feline sporotrichosis outbreak in metropolitan Recife. Pesqui. Vet. Bras. 2018;38:1767-1771.

    Not in our library10.1590/1678-5150-pvb-5027

  148. 148.

    Marques-Melo E.H., Lessa D.F.d.S., Garrido L.H.A., Nunes A.C.B.T., Chaves K.P., Porto W.J.N., Notomi M. Domestic feline as sporotricosis transmitting agent for human: Report of the first case in the state of Alagoas. Rev. Baiana De Saúde Pública. 2014;38:490-498.

    Not in our library

  149. 149.

    Madrid I.M., Mattei A., Martins A., Nobre M., Meireles M. Feline sporotrichosis in the southern region of Rio Grande do Sul, Brazil: Clinical, zoonotic and therapeutic aspects. Zoonoses Public Health. 2010;57:151-154.

    Not in our library10.1111/j.1863-2378.2008.01227.x

  150. 150.

    Sanchotene K.O., Madrid I.M., Klafke G.B., Bergamashi M., Terra P.P.D., Rodrigues A.M., de Camargo Z.P., Xavier M.O. Sporothrix brasiliensis outbreaks and the rapid emergence of feline sporotrichosis. Mycoses. 2015;58:652-658.

    Not in our library10.1111/myc.12414

  151. 151.

    Madrid I.M., Mattei A.S., Fernandes C.G., Oliveira Nobre M., Meireles M.C.A. Epidemiological findings and laboratory evaluation of sporotrichosis: A description of 103 cases in cats and dogs in Southern Brazil. Mycopathologia. 2012;173:265-273.

    Not in our library10.1007/s11046-011-9509-4

  152. 152.

    Eudes Filho J., Santos I.B.D., Reis C.M.S., Patané J.S.L., Paredes V., Bernardes J., Poggiani S., Castro T.C.B., Gomez O.M., Pereira S.A., et al. A novel Sporothrix brasiliensis genomic variant in Midwestern Brazil: Evidence for an older and wider sporotrichosis epidemic. Emerg. Microbes Infect. 2020;9:2515-2525.

    Not in our library10.1080/22221751.2020.1847001

  153. 153.

    Bernardes-Engemann A.R., Almeida M.A., Bison I., Rabello V.B.S., Ramos M.L.M., Pereira S.A., Almeida-Paes R., de Lima Brasil A.W., Zancopé-Oliveira R.M. Anti-Sporothrix Antibody Detection in Domestic Cats as an Indicator of a Possible New Occurrence Area for Sporotrichosis in North Brazil. Mycopathologia. 2022;1-10.

    Not in our library10.1007/s11046-022-00644-7

  154. 154.

    Schmidt P.M., Lopez R.R., Collier B.A. Survival, fecundity, and movements of free-roaming cats. J. Wildl. Manag. 2007;71:915-919.

    Not in our library10.2193/2006-066

  155. 155.

    Jongman E.C. Adaptation of domestic cats to confinement. J. Vet. Behav. 2007;2:193-196.

    Not in our library10.1016/j.jveb.2007.09.003

  156. 156.

    Horn J.A., Mateus-Pinilla N., Warner R.E., Heske E.J. Home range, habitat use, and activity patterns of free-roaming domestic cats. J. Wildl. Manag. 2011;75:1177-1185.

    Not in our library10.1002/jwmg.145

  157. 157.

    Keesing F., Belden L.K., Daszak P., Dobson A., Harvell C.D., Holt R.D., Hudson P., Jolles A., Jones K.E., Mitchell C.E., et al. Impacts of biodiversity on the emergence and transmission of infectious diseases. Nature. 2010;468:647-652.

    Not in our library10.1038/nature09575

  158. 158.

    Jones K.E., Patel N.G., Levy M.A., Storeygard A., Balk D., Gittleman J.L., Daszak P. Global trends in emerging infectious diseases. Nature. 2008;451:990-993.

    Not in our library10.1038/nature06536

  159. 159.

    Shaheen M.N.F. The concept of one health applied to the problem of zoonotic diseases. Rev. Med. Virol. 2022;32:e2326.

    Not in our library10.1002/rmv.2326

  160. 160.

    Winck G.R., Raimundo R.L.G., Fernandes-Ferreira H., Bueno M.G., D’Andrea P.S., Rocha F.L., Cruz G.L.T., Vilar E.M., Brandão M., Cordeiro J.L.P., et al. Socioecological vulnerability and the risk of zoonotic disease emergence in Brazil. Sci. Adv. 2022;8:eabo5774.

    Not in our library10.1126/sciadv.abo5774

  161. 161.
    Infectious Disease Threats in the Twenty-First Century: Strengthening the Global Response · 2019
    No notice
  162. 162.

    Alzuguir C.L.C., Pereira S.A., Magalhães M.A.F.M., Almeida-Paes R., Freitas D.F.S., Oliveira L.F.A., Pimentel M.I.F. Geo-epidemiology and socioeconomic aspects of human sporotrichosis in the municipality of Duque de Caxias, Rio de Janeiro, Brazil, between 2007 and 2016. Trans. R. Soc. Trop. Med. Hyg. 2020;114:99-106.

    Not in our library10.1093/trstmh/trz081

  163. 163.

    Silva M.B., Costa M.M., Torres C.C., Galhardo M.C., Valle A.C., Magalhaes Mde A., Sabroza P.C., Oliveira R.M. [Urban sporotrichosis: A neglected epidemic in Rio de Janeiro, Brazil]. Cad. De Saude Publica. 2012;28:1867-1880.

    Not in our library10.1590/s0102-311x2012001000006

  164. 164.

    Veasey J.V., Carvalho G.d.S.M., Ruiz L.R.B., Neves Neto M.F., Zaitz C. Epidemiological and geographical distribution profile of urban sporotrichosis in the city of São Paulo. An. Bras. De Dermatol. 2022;97:228-230.

    Not in our library10.1016/j.abd.2020.11.014

  165. 165.

    Ellwanger J.H., Kulmann-Leal B., Kaminski V.L., Valverde-Villegas J.M., Veiga A., Spilki F.R., Fearnside P.M., Caesar L., Giatti L.L., Wallau G.L., et al. Beyond diversity loss and climate change: Impacts of Amazon deforestation on infectious diseases and public health. An. Da Acad. Bras. De Cienc. 2020;92:e20191375.

    Not in our library10.1590/0001-3765202020191375

  166. 166.

    Pörtner H.-O., Roberts D.C., Adams H., Adelekan I., Adler C., Adrian R., Aldunce P., Ali E., Ara Begum R., Bednar-Friedl B., Pörtner H.-O., Roberts D.C., Tignor M., Poloczanska E.S., Mintenbeck K., Alegría A., Craig M., Langsdorf S., Löschke S., Möller V., et al. IPCC, 2022: Climate Change 2022: Impacts, Adaptation, and Vulnerability: Contribution of Working Group II to the Sixth Assessment Report of the Intergovernmental Panel on Climate Change. 2022.

    Not in our library

  167. 167.

    Jones Bryony A., Grace D., Kock R., Alonso S., Rushton J., Said Mohammed Y., McKeever D., Mutua F., Young J., McDermott J., et al. Zoonosis emergence linked to agricultural intensification and environmental change. Proc. Natl. Acad. Sci. USA. 2013;110:8399-8404.

    Not in our library10.1073/pnas.1208059110

  168. 168.

    Rabello V.B.S., Almeida-Silva F., Scramignon-Costa B.d.S., Motta B.d.S., de Macedo P.M., Teixeira M.d.M., Almeida-Paes R., Irinyi L., Meyer W., Zancopé-Oliveira R.M. Environmental isolation of Sporothrix brasiliensis in an area with recurrent feline sporotrichosis cases. Front. Cell. Infect. Microbiol. 2022;12:894297.

    Not in our library10.3389/fcimb.2022.894297

  169. 169.

    Almeida-Silva F., Rabello V.B., Scramignon-Costa B.D., Zancopé-Oliveira R.M., de Macedo P.M., Almeida-Paes R. Beyond domestic cats: Environmental detection of Sporothrix brasiliensis DNA in a hyperendemic area of sporotrichosis in Rio de Janeiro state, Brazil. J. Fungi. 2022;8:604.

    Not in our library10.3390/jof8060604

  170. 170.

    Navarrete A.A., Tsai S.M., Mendes L.W., Faust K., de Hollander M., Cassman N.A., Raes J., van Veen J.A., Kuramae E.E. Soil microbiome responses to the short-term effects of Amazonian deforestation. Mol. Ecol. 2015;24:2433-2448.

    Not in our library10.1111/mec.13172

  171. 171.

    Khan M.A.W., Bohannan B.J.M., Nüsslein K., Tiedje J.M., Tringe S.G., Parlade E., Barberán A., Rodrigues J.L.M. Deforestation impacts network co-occurrence patterns of microbial communities in Amazon soils. FEMS Microbiol. Ecol. 2019;95:fiy230.

    Not in our library10.1093/femsec/fiy230

  172. 172.

    Rosenberg K., Bertaux J., Krome K., Hartmann A., Scheu S., Bonkowski M. Soil amoebae rapidly change bacterial community composition in the rhizosphere of Arabidopsis thaliana. ISME J. 2009;3:675-684.

    Not in our library10.1038/ismej.2009.11

  173. 173.

    Steenbergen J.N., Nosanchuk J.D., Malliaris S.D., Casadevall A. Interaction of Blastomyces dermatitidis, Sporothrix schenckii, and Histoplasma capsulatum with Acanthamoeba castellanii. Infect. Immun. 2004;72:3478-3488.

    Not in our library10.1128/iai.72.6.3478-3488.2004

  174. 174.

    Lemos Tavares P., Carvalho Ribeiro A., Kercher Berte F., da Silva Hellwig A.H., Machado Pagani D., Tavares de Souza C.C., Brittes Rott M., Scroferneker M.L. The interaction between Sporothrix schenckii sensu stricto and Sporothrix brasiliensis with Acanthamoeba castellanii. Mycoses. 2020;63:302-307.

    Not in our library10.1111/myc.13043

  175. 175.

    Aqeel Y., Siddiqui R., Iftikhar H., Khan N.A. The effect of different environmental conditions on the encystation of Acanthamoeba castellanii belonging to the T4 genotype. Exp. Parasitol. 2013;135:30-35.

    Not in our library10.1016/j.exppara.2013.05.017

  176. 176.

    Rossow J.A., Queiroz-Telles F., Caceres D.H., Beer K.D., Jackson B.R., Pereira J.G., Ferreira Gremião I.D., Pereira S.A. A one health approach to combatting Sporothrix brasiliensis: Narrative review of an emerging zoonotic fungal pathogen in South America. J. Fungi. 2020;6:247.

    Not in our library10.3390/jof6040247

  177. 177.
    Sporotrichosis: An Overview and Therapeutic Options · 2014
    No notice
  178. 178.

    Lopes-Bezerra L.M., Mora-Montes H.M., Zhang Y., Nino-Vega G., Rodrigues A.M., de Camargo Z.P., de Hoog S. Sporotrichosis between 1898 and 2017: The evolution of knowledge on a changeable disease and on emerging etiological agents. Med. Mycol. 2018;56:126-143.

    Not in our library10.1093/mmy/myx103

  179. 179.

    Kwon-Chung J.K., Bennett J.E. Medical Mycology. 1992.

    Not in our library

  180. 180.

    Rippon J.W. Medical Mycology—The Pathogenic Fungi and the Pathogenic Actinomycetes. 1988.

    Not in our library

  181. 181.

    Rodrigues A.M., Orofino-Costa R., de Camargo Z.P., Cordeiro Rde A. Sporothrix spp. Pocket Guide to Mycological Diagnosis. 2019;99-113.

    Not in our library10.1201/b22205

  182. 182.

    Rodrigues A.M., de Hoog G.S., de Camargo Z.P., Seyedmousavi S., de Hoog G.S., Guillot J., Verweij P.E. Feline Sporotrichosis. Emerging and Epizootic Fungal Infections in Animals. 2018;Volume 1:199-231.

    Not in our library

  183. 183.

    Miranda L.H., Quintella L.P., Menezes R.C., dos Santos I.B., Oliveira R.V., Figueiredo F.B., Lopes-Bezerra L.M., Schubach T.M. Evaluation of immunohistochemistry for the diagnosis of sporotrichosis in dogs. Vet. J. 2011;190:408-411.

    Not in our library10.1016/j.tvjl.2010.12.004

  184. 184.

    Bernardes-Engemann A.R., de Lima Barros M., Zeitune T., Russi D.C., Orofino-Costa R., Lopes-Bezerra L.M. Validation of a serodiagnostic test for sporotrichosis: A follow-up study of patients related to the Rio de Janeiro zoonotic outbreak. Med. Mycol. 2015;53:28-33.

    Not in our library10.1093/mmy/myu058

  185. 185.

    Gezuele E., Da Rosa D. Importance of the sporotrichosis asteroid body for the rapid diagnosis of sporotrichosis. Rev. Iberoam. De Micol. 2005;22:147-150.

    Not in our library10.1016/s1130-1406(05)70028-0

  186. 186.

    Schwarz J. The diagnosis of deep mycoses by morphologic methods. Hum. Pathol. 1982;13:519-533.

    Not in our library10.1016/s0046-8177(82)80267-0

  187. 187.

    Morris-Jones R. Sporotrichosis. Clin. Exp. Dermatol. 2002;27:427-431.

    Not in our library10.1046/j.1365-2230.2002.01087.x

  188. 188.

    de Lima Barros M.B., Schubach A.O., de Vasconcellos Carvalhaes de Oliveira R., Martins E.B., Teixeira J.L., Wanke B. Treatment of cutaneous sporotrichosis with Itraconazole—Study of 645 patients. Clin. Infect. Dis. 2011;52:e200-e206.

    Not in our library10.1093/cid/cir245

  189. 189.

    Rodrigues A.M., Hagen F., de Camargo Z.P. A spotlight on Sporothrix and sporotrichosis. Mycopathologia. 2022;1-5.

    Not in our library10.1007/s11046-022-00642-9

  190. 190.

    Gonçalves S.S., Cano J.F., Stchigel A.M., Melo A.S., Godoy-Martinez P.C., Correa B., Guarro J. Molecular phylogeny and phenotypic variability of clinical and environmental strains of Aspergillus flavus. Fungal Biol. 2012;116:1146-1155.

    Not in our library10.1016/j.funbio.2012.08.006

  191. 191.

    Silva J.N., Miranda L.H.M., Menezes R.C., Gremiao I.D.F., Oliveira R.V.C., Vieira S.M.M., Conceicao-Silva F., Ferreiro L., Pereira S.A. Comparison of the sensitivity of three methods for the early diagnosis of sporotrichosis in cats. J. Comp. Pathol. 2018;160:72-78.

    Not in our library10.1016/j.jcpa.2018.03.002

  192. 192.

    Rodrigues A.M., Fernandes G.F., de Camargo Z.P., Bayry J. Sporotrichosis. Emerging and Re-Emerging Infectious Diseases of Livestock. 2017;391-421.

    Not in our library10.1007/978-3-319-47426-7_19

  193. 193.

    Marimon R., Gené J., Cano J., Guarro J. Sporothrix luriei: A rare fungus from clinical origin. Med. Mycol. 2008;46:621-625.

    Not in our library10.1080/13693780801992837

  194. 194.

    Oliveira M.M., Almeida-Paes R., Muniz M.M., Gutierrez-Galhardo M.C., Zancope-Oliveira R.M. Phenotypic and molecular identification of Sporothrix isolates from an epidemic area of sporotrichosis in Brazil. Mycopathologia. 2011;172:257-267.

    Not in our library10.1007/s11046-011-9437-3

  195. 195.

    Zhao M.-d., Zhou X., Liu T.-t., Yang Z.-b. Morphological and physiological comparison of taxa comprising the Sporothrix schenckii complex. J. Zhejiang Univ. Sci. B. 2015;16:940-947.

    Not in our library10.1631/jzus.b1500055

  196. 196.

    Vásquez-del-Mercado E., Arenas R., Padilla-Desgarenes C. Sporotrichosis. Clin. Derm. 2012;30:437-443.

    Not in our library10.1016/j.clindermatol.2011.09.017

  197. 197.

    Richardson M.D., Warnock D.W. Fungal Infection: Diagnosis and Management. 2012.

    Not in our library

  198. 198.

    Oyarce J.A., García C., Alave J., Bustamante B. Epidemiological clinical and laboratory characterization of sporotrichosis in patients of a tertiary care hospital in Lima, Peru, from 1991 to 2014. Rev. Chil. Infectol. 2016;33:315-321.

    Not in our library10.4067/s0716-10182016000300012

  199. 199.

    Arenas R., Sanchez-Cardenas C.D., Ramirez-Hobak L., Ruiz Arriaga L.F., Vega Memije M.E. Sporotrichosis: From KOH to molecular biology. J. Fungi. 2018;4:62.

    Not in our library10.3390/jof4020062

  200. 200.

    Quintella L.P., Passos S.R., do Vale A.C., Galhardo M.C., Barros M.B., Cuzzi T., Reis Rdos S., de Carvalho M.H., Zappa M.B., Schubach Ade O. Histopathology of cutaneous sporotrichosis in Rio de Janeiro: A series of 119 consecutive cases. J. Cutan. Pathol. 2011;38:25-32.

    Not in our library10.1111/j.1600-0560.2010.01626.x

  201. 201.

    Quintella L.P., Passos S.R., de Miranda L.H., Cuzzi T., Barros M.B., Francesconi-do-Vale A.C., Galhardo M.C., Madeira Mde F., Figueiredo de Carvalho M.H., Schubach Ade O. Proposal of a histopathological predictive rule for the differential diagnosis between American tegumentary leishmaniasis and sporotrichosis skin lesions. Br. J. Dermatol. 2012;167:837-846.

    Not in our library10.1111/j.1365-2133.2012.11012.x

  202. 202.

    da Rosa W.D., Gezuele E., Calegari L., Goni F. Asteroid body in sporotrichosis. Yeast viability and biological significance within the host immune response. Med. Mycol. 2008;46:443-448.

    Not in our library10.1080/13693780801914898

  203. 203.

    Civila E.S., Bonasse J., Conti-Diaz I.A., Vignale R.A. Importance of the direct fresh examination in the diagnosis of cutaneous sporotrichosis. Int. J. Derm. 2004;43:808-810.

    Not in our library10.1111/j.1365-4632.2004.02271.x

  204. 204.

    Miranda L.H., Conceicao-Silva F., Quintella L.P., Kuraiem B.P., Pereira S.A., Schubach T.M. Feline sporotrichosis: Histopathological profile of cutaneous lesions and their correlation with clinical presentation. Comp. Immunol. Microbiol. Infect. Dis. 2013;36:425-432.

    Not in our library10.1016/j.cimid.2013.03.005

  205. 205.

    Welsh R.D. Sporotrichosis. J. Am. Vet. Med. Assoc. 2003;223:1123-1126.

    Not in our library10.2460/javma.2003.223.1123

  206. 206.

    Pereira S.A., Menezes R.C., Gremião I.D.F., Silva J.N., de O. Honse C., Figueiredo C., da Silva D.T., Kitada A.A.B., dos Reis É.G., Schubach T.M.P. Sensitivity of cytopathological examination in the diagnosis of feline sporotrichosis. J. Feline Med. Surg. 2011;13:220-223.

    Not in our library10.1016/j.jfms.2010.10.007

  207. 207.

    Seyedmousavi S., Bosco S.d.M.G., de Hoog S., Ebel F., Elad D., Gomes R.R., Jacobsen I.D., Jensen H.E., Martel A., Mignon B., et al. Fungal infections in animals: A patchwork of different situations. Med. Mycol. 2018;56:165-187.

    Not in our library10.1093/mmy/myx104

  208. 208.

    Gonsales F.F., Fernandes N., Mansho W., Montenegro H., Guerra J.M., de Araujo L.J.T., da Silva S.M.P., Benites N.R. Feline Sporothrix spp. detection using cell blocks from brushings and fine-needle aspirates: Performance and comparisons with culture and histopathology. Vet. Clin. Pathol. 2019;48:143-147.

    Not in our library10.1111/vcp.12708

  209. 209.

    Zhang Y.Q., Xu X.G., Zhang M., Jiang P., Zhou X.Y., Li Z.Z., Zhang M.F. Sporotrichosis: Clinical and histopathological manifestations. Am. J. Dermatopathol. 2011;33:296-302.

    Not in our library10.1097/dad.0b013e3181f5b622

  210. 210.

    Hussein M.R. Mucocutaneous Splendore-Hoeppli phenomenon. J. Cutan. Pathol. 2008;35:979-988.

    Not in our library10.1111/j.1600-0560.2008.01045.x

  211. 211.

    Widal F., Aerami P., Joltrain E., Brissaud E.T., Weill A. Serodiagnostic mycosique, applications au diagnostic de la sporotrichose et de l’actinomycose. Les coagulations et cofixations mycosiques. Ann. Inst. Pasteur. 1910;24:1-33.

    Not in our library

  212. 212.

    Ochoa A.G., Figueroa E. Polisacaridos del Sporotrichum schenckii. Datos immunologicos: Intradermoreaccion en el diagnostico de la esporotrichosis. Rev. Inst. Salubr. Enferm. Trop. 1947;8:143-153.

    Not in our library

  213. 213.

    Blumer S.O., Kaufman L., Kaplan W., McLaughlin D.W., Kraft D.E. Comparative evaluation of five serological methods for the diagnosis of sporotrichosis. Appl. Microbiol. 1973;26:4-8.

    Not in our library10.1128/am.26.1.4-8.1973

  214. 214.

    Velasco O., Ochoa A.G. Sporotrichosis in patients with previous positive sporotrichin reaction. Rev. De Investig. En Salud Publica. 1971;31:53-55.

    Not in our library

  215. 215.

    Ghosh A., Chakrabarti A., Sharma V.K., Singh K., Singh A. Sporotrichosis in Himachal Pradesh (north India). Trans. R. Soc. Trop. Med. Hyg. 1999;93:41-45.

    Not in our library10.1016/s0035-9203(99)90173-6

  216. 216.

    Bonifaz A., Vázquez-González D. Sporotrichosis: An update. G Ital Derm. Venereol. 2010;145:659-673.

    Not in our library

  217. 217.

    Kusuhara M. Sporotrichosis and dematiaceous fungal skin infections. Nihon Ishinkin Gakkai Zasshi. 2009;50:213-217.

    Not in our library10.3314/jjmm.50.213

  218. 218.

    Itoh M., Okamoto S., Kariya H. Survey of 200 cases of sporotrichosis. Dermatologica. 1986;172:209-213.

    Not in our library10.1159/000249337

  219. 219.

    Kusuhara M., Hachisuka H., Sasai Y. Statistical survey of 150 cases with sporotrichosis. Mycopathologia. 1988;102:129-133.

    Not in our library10.1007/bf00437450

  220. 220.

    Posada H.R. Prueba cutanea con esporotricina. Mycopathologia. 1968;36:42-54.

    Not in our library10.1007/bf02057165

  221. 221.

    Bonifaz A., Toriello C., Araiza J., Ramírez-Soto M.C., Tirado-Sánchez A. Sporotrichin skin test for the diagnosis of sporotrichosis. J. Fungi. 2018;4:55.

    Not in our library10.3390/jof4020055

  222. 222.

    Bernardes-Engemann A.R., Orofino Costa R.C., Miguens B.P., Penha C.V.L., Neves E., Pereira B.A.S., Dias C.M.P., Mattos M., Gutierrez M.C., Schubach A., et al. Development of an enzyme-linked immunosorbent assay for the serodiagnosis of several clinical forms of sporotrichosis. Med. Mycol. 2005;43:487-493.

    Not in our library10.1080/13693780400019909

  223. 223.

    López-Ribot J.L., Casanova M., Murgui A., Martínez J.P. Antibody response to Candida albicans cell wall antigens. FEMS Immunol. Med. Microbiol. 2004;41:187-196.

    Not in our library10.1016/j.femsim.2004.03.012

  224. 224.

    Alba-Fierro C.A., Pérez-Torres A., López-Romero E., Cuéllar-Cruz M., Ruiz-Baca E. Cell wall proteins of Sporothrix schenckii as immunoprotective agents. Rev. Iberoam. De Micol. 2014;31:86-89.

    Not in our library10.1016/j.riam.2013.09.017

  225. 225.

    Fernandes G.F., Lopes-Bezerra L.M., Bernardes-Engemann A.R., Schubach T.M., Dias M.A., Pereira S.A., de Camargo Z.P. Serodiagnosis of sporotrichosis infection in cats by enzyme-linked immunosorbent assay using a specific antigen, SsCBF, and crude exoantigens. Vet. Microbiol. 2011;147:445-449.

    Not in our library10.1016/j.vetmic.2010.07.007

  226. 226.

    Penha C.V., Bezerra L.M. Concanavalin A-binding cell wall antigens of Sporothrix schenckii: A serological study. Med. Mycol. 2000;38:1-7.

    Not in our library10.1080/mmy.38.1.1.7

  227. 227.

    Alvarado P., Ostos A., Franquiz N., Roschman-González A., Zambrano E.A., Mendoza M. Serological diagnosis of sporotrichosis using an antigen of Sporothrix schenckii sensu stricto mycelium. Investig. Clin. 2015;56:111-122.

    Not in our library

  228. 228.

    Fernandes G.F., Amaral C.C.D., Sasaki A., Godoy P.M., De Camargo Z.P. Heterogeneity of proteins expressed by Brazilian Sporothrix schenckii isolates. Med. Mycol. 2009;47:855-861.

    Not in our library10.3109/13693780802713216

  229. 229.

    Bernardes-Engemann A.R., Loureiro y Penha C.V., Benvenuto F., Braga J.U., Barros M.L., Orofino-Costa R., Lopes-Bezerra L.M. A comparative serological study of the SsCBF antigenic fraction isolated from three Sporothrix schenckii strains. Med. Mycol. 2009;47:874-878.

    Not in our library10.3109/13693780802695520

  230. 230.

    Rodrigues A.M., Kubitschek-Barreira P.H., Fernandes G.F., de Almeida S.R., Lopes-Bezerra L.M., de Camargo Z.P. Immunoproteomic analysis reveals a convergent humoral response signature in the Sporothrix schenckii complex. J. Proteom. 2015;115:8-22.

    Not in our library10.1016/j.jprot.2014.11.013

  231. 231.

    Martínez-Álvarez J.A., García-Carnero L.C., Kubitschek-Barreira P.H., Lozoya-Pérez N.E., Belmonte-Vázquez J.L., de Almeida J.R., Gómez-Infante A.D.J., Curty N., Villagómez-Castro J.C., Peña-Cabrera E., et al. Analysis of some immunogenic properties of the recombinant Sporothrix schenckii Gp70 expressed in Escherichia coli. Future Microbiol. 2019;14:397-410.

    Not in our library10.2217/fmb-2018-0295

  232. 232.

    Baptista V.S., Mothé G.B., Santos G.M.P., Melivilu C.S.I., Santos T.O., Virginio E.D., de Macêdo-Sales P.A., Pinto M.R., Machado R.L.D., Rocha E.M.S., et al. Promising application of the SsCBF ELISA test to monitor the therapeutic response of feline sporotrichosis caused by Sporothrix brasiliensis from Brazilian epidemics. Braz. J. Microbiol. 2021;52:145-153.

    Not in our library10.1007/s42770-020-00362-6

  233. 233.

    Elias Costa M.R., Da Silva Lacaz C., Kawasaki M., De Camargo Z.P. Conventional versus molecular diagnostic tests. Med. Mycol. 2000;38((Suppl. 1)):139-145.

    Not in our library10.1080/mmy.38.s1.139.145

  234. 234.

    Ghosh A., Maity P.K., Hemashettar B.M., Sharma V.K., Chakrabarti A. Physiological characters of Sporothrix schenckii isolates. Mycoses. 2002;45:449-554.

    Not in our library

  235. 235.

    Mesa-Arango A.C., del Rocío Reyes-Montes M., Pérez-Mejía A., Navarro-Barranco H., Souza V., Zúñiga G., Toriello C. Phenotyping and genotyping of Sporothrix schenckii isolates according to geographic origin and clinical form of sporotrichosis. J. Clin. Microbiol. 2002;40:3004-3011.

    Not in our library10.1128/jcm.40.8.3004-3011.2002

  236. 236.

    Lücking R., Aime M.C., Robbertse B., Miller A.N., Aoki T., Ariyawansa H.A., Cardinali G., Crous P.W., Druzhinina I.S., Geiser D.M., et al. Fungal taxonomy and sequence-based nomenclature. Nat. Microbiol. 2021;6:540-548.

    Not in our library10.1038/s41564-021-00888-x

  237. 237.
    Fusarium: more than a node or a foot-shaped basal cell · 2021
    No notice
  238. 238.

    Della Terra P.P., Gonsales F.F., de Carvalho J.A., Hagen F., Kano R., Bonifaz A., Camargo Z.P., Rodrigues A.M. Development and evaluation of a multiplex qPCR assay for rapid diagnostics of emerging sporotrichosis. Transbound. Emerg. Dis. 2021.

    Not in our library10.1111/tbed.14350

  239. 239.

    Pinheiro B.G., Hahn R.C., Camargo Z.P., Rodrigues A.M. Molecular tools for detection and identification of Paracoccidioides species: Current status and future perspectives. J. Fungi. 2020;6:293.

    Not in our library10.3390/jof6040293

  240. 240.

    de Carvalho J.A., Monteiro R.C., Hagen F., Camargo Z.P., Rodrigues A.M. Trends in molecular diagnostics and genotyping tools applied for emerging Sporothrix species. J. Fungi. 2022.

    Not in our library10.3390/jof8080809

  241. 241.

    Hu S., Chung W.-H., Hung S.-I., Ho H.-C., Wang Z.-W., Chen C.-H., Lu S.-C., Kuo T.-T., Hong H.-S. Detection of Sporothrix schenckii in clinical samples by a nested PCR assay. J. Clin. Microbiol. 2003;41:1414-1418.

    Not in our library10.1128/jcm.41.4.1414-1418.2003

  242. 242.

    Kano R., Nakamura Y., Watanabe S., Tsujimoto H., Hasegawa A. Identification of Sporothrix schenckii based on sequences of the chitin synthase 1 gene. Mycoses. 2001;44:261-265.

    Not in our library10.1111/j.1439-0507.2001.00655.x

  243. 243.

    Kano R., Matsuoka A., Kashima M., Nakamura Y., Watanabe S., Mizoguchi M., Hasegawa A. Detection of Sporothrix schenckii chitin synthase 1 (CHS1) gene in biopsy specimens from human patients with sporotrichosis. J. Derm. Sci. 2003;33:73-74.

    Not in our library10.1016/s0923-1811(03)00153-1

  244. 244.

    Mendoza M., Brito A., Schaper D.A., Spooner V.A., Alvarado P., Castro A., Fernandez A. Technical evaluation of nested PCR for the diagnosis of experimental sporotrichosis. Rev. Iberoam. De Micol. 2012;29:120-125.

    Not in our library10.1016/j.riam.2011.09.002

  245. 245.

    Zhang M., Li F., Gong J., Yang X., Zhang J., Zhao F. Development and evaluation of a real-time polymerase chain reaction for fast diagnosis of sporotrichosis caused by Sporothrix globosa. Med. Mycol. 2019;58:61-65.

    Not in our library10.1093/mmy/myz029

  246. 246.

    Rodrigues A.M., de Hoog G.S., Camargo Z.P. Genotyping species of the Sporothrix schenckii complex by PCR-RFLP of calmodulin. Diagn Microbiol. Infect. Dis. 2014;78:383-387.

    Not in our library10.1016/j.diagmicrobio.2014.01.004

  247. 247.

    Rodrigues A.M., Najafzadeh M.J., de Hoog G.S., de Camargo Z.P. Rapid identification of emerging human-pathogenic Sporothrix species with rolling circle amplification. Front. Microbiol. 2015;6:1385.

    Not in our library10.3389/fmicb.2015.01385

  248. 248.

    Ramírez-Soto M.C., Aguilar-Ancori E.G., Quispe-Ricalde M.A., Muñiz-Duran J.G., Quispe-Florez M.M., Chinen A. Molecular identification of Sporothrix species in a hyperendemic area in Peru. J. Infect. Public. Health. 2021;14:670-673.

    Not in our library10.1016/j.jiph.2021.02.005

  249. 249.

    Gonsales F.F., Fernandes N.C.C.A., Mansho W., Montenegro H., Benites N.R. Direct PCR of lesions suggestive of sporotrichosis in felines. Arq. Bras. Med. Vet. Zootec. 2020;72:2002-2006.

    Not in our library10.1590/1678-4162-11743

  250. 250.

    Zhang M., Li F., Li R., Gong J., Zhao F. Fast diagnosis of sporotrichosis caused by Sporothrix globosa, Sporothrix schenckii, and Sporothrix brasiliensis based on multiplex real-time PCR. PLoS Negl. Trop. Dis. 2019;13:e0007219.

    Not in our library10.1371/journal.pntd.0007219

  251. 251.

    Madrid H., Gené J., Cano J., Silvera C., Guarro J. Sporothrix brunneoviolacea and Sporothrix dimorphospora, two new members of the Ophiostoma stenoceras-Sporothrix schenckii complex. Mycologia. 2010;102:1193-1203.

    Not in our library10.3852/09-320

  252. 252.

    Rangel-Gamboa L., Martinez-Hernandez F., Maravilla P., Arenas-Guzman R., Flisser A. Update of phylogenetic and genetic diversity of Sporothrix schenckii sensu lato. Med. Mycol. 2016;54:248-255.

    Not in our library10.1093/mmy/myv096

  253. 253.

    de Carvalho J.A., Hagen F., Fisher M.C., de Camargo Z.P., Rodrigues A.M. Genome-wide mapping using new AFLP markers to explore intraspecific variation among pathogenic Sporothrix species. PLoS Negl. Trop. Dis. 2020;14:e0008330.

    Not in our library10.1371/journal.pntd.0008330

  254. 254.

    Restrepo C.M., Llanes A., Lleonart R. Use of AFLP for the study of eukaryotic pathogens affecting humans. Infect. Genet. Evol. 2018;63:360-369.

    Not in our library10.1016/j.meegid.2017.09.017

  255. 255.

    Roberto T.N., De Carvalho J.A., Beale M.A., Hagen F., Fisher M.C., Hahn R.C., de Camargo Z.P., Rodrigues A.M. Exploring genetic diversity, population structure, and phylogeography in Paracoccidioides species using AFLP markers. Stud. Mycol. 2021;100:100131.

    Not in our library10.1016/j.simyco.2021.100131

  256. 256.

    Rodrigues A.M., Beale M.A., Hagen F., Fisher M.C., Terra P.P.D., de Hoog S., Brilhante R.S.N., de Aguiar Cordeiro R., de Souza Collares Maia Castelo-Branco D., Rocha M.F.G., et al. The global epidemiology of emerging Histoplasma species in recent years. Stud. Mycol. 2020;97:100095.

    Not in our library10.1016/j.simyco.2020.02.001

  257. 257.
    MALDI-TOF mass spectrometry: an emerging technology for microbial identification and diagnosis · 2015
    No notice
  258. 258.

    Murray P.R. What is new in clinical microbiology-microbial identification by MALDI-TOF mass spectrometry: A paper from the 2011 William Beaumont Hospital Symposium on molecular pathology. J. Mol. Diagn. JMD. 2012;14:419-423.

    Not in our library10.1016/j.jmoldx.2012.03.007

  259. 259.

    Oliveira M.M., Santos C., Sampaio P., Romeo O., Almeida-Paes R., Pais C., Lima N., Zancope-Oliveira R.M. Development and optimization of a new MALDI-TOF protocol for identification of the Sporothrix species complex. Res. Microbiol. 2015;166:102-110.

    Not in our library10.1016/j.resmic.2014.12.008

  260. 260.

    Etchecopaz A., Toscanini M.A., Gisbert A., Mas J., Scarpa M., Iovannitti C.A., Bendezú K., Nusblat A.D., Iachini R., Cuestas M.L. Sporothrix brasiliensis: A review of an emerging South American fungal pathogen, its related disease, presentation and spread in Argentina. J. Fungi. 2021;7:170.

    Not in our library10.3390/jof7030170

  261. 261.

    Matos A.M.F., Moreira L.M., Barczewski B.F., de Matos L.X., de Oliveira J.B.V., Pimentel M.I.F., Almeida-Paes R., Oliveira M.G., Pinto T.C.A., Lima N., et al. Identification by MALDI-TOF MS of Sporothrix brasiliensis isolated from a subconjunctival infiltrative lesion in an immunocompetent patient. Microorganisms. 2019;8:22.

    Not in our library10.3390/microorganisms8010022

  262. 262.

    Espinel-Ingroff A., Abreu D.P.B., Almeida-Paes R., Brilhante R.S.N., Chakrabarti A., Chowdhary A., Hagen F., Cordoba S., Gonzalez G.M., Govender N.P., et al. Multicenter and international study of MIC/MEC distributions for definition of epidemiological cutoff values (ECVs) for species of Sporothrix identified by molecular methods. Antimicrob. Agents Chemother. 2017;61:e01057-17.

    Not in our library10.1128/aac.01057-17

  263. 263.

    Costa R.O., Macedo P.M., Carvalhal A., Bernardes-Engemann A.R. Use of potassium iodide in dermatology: Updates on an old drug. An. Bras. De Dermatol. 2013;88:396-402.

    Not in our library10.1590/abd1806-4841.20132377

  264. 264.

    Brilhante R.S.N., Silva M., Pereira V.S., de Oliveira J.S., Maciel J.M., Silva I., Garcia L.G.S., Guedes G.M.M., Cordeiro R.A., Pereira-Neto W.A., et al. Potassium iodide and miltefosine inhibit biofilms of Sporothrix schenckii species complex in yeast and filamentous forms. Med. Mycol. 2018;57:764-772.

    Not in our library10.1093/mmy/myy119

  265. 265.

    Sharma B., Sharma A.K., Sharma U. Sporotrichosis: A comprehensive review on recent drug-based therapeutics and management. Curr. Derm. Rep. 2022;11:110-119.

    Not in our library10.1007/s13671-022-00358-5

  266. 266.

    Gremião I.D.F., Miranda L.H.M.d., Pereira-Oliveira G.R., Menezes R.C., Machado A.C.d.S., Rodrigues A.M., Pereira S.A. Advances and challenges in the management of feline sporotrichosis. Rev. Iberoam. Micol. 2022;S1130-1406(22)00021-3.

    Not in our library10.1016/j.riam.2022.05.002

  267. 267.

    Borba-Santos L.P., Rodrigues A.M., Gagini T.B., Fernandes G.F., Castro R., de Camargo Z.P., Nucci M., Lopes-Bezerra L.M., Ishida K., Rozental S. Susceptibility of Sporothrix brasiliensis isolates to amphotericin B, azoles, and terbinafine. Med. Mycol. 2015;53:178-188.

    Not in our library10.1093/mmy/myu056

  268. 268.

    CDDI. Cortellis Drug Discovery Intelligence Database.

    Not in our library

  269. 269.

    Francesconi G., Francesconi do Valle A.C., Passos S.L., de Lima Barros M.B., de Almeida Paes R., Curi A.L., Liporage J., Porto C.F., Galhardo M.C. Comparative study of 250 mg/day terbinafine and 100 mg/day itraconazole for the treatment of cutaneous sporotrichosis. Mycopathologia. 2011;171:349-354.

    Not in our library10.1007/s11046-010-9380-8

  270. 270.
    Amphotericin B and Other Polyenes—Discovery, Clinical Use, Mode of Action and Drug Resistance · 2020
    No notice
  271. 271.

    Institute C.a.L.S. Reference Method for Broth Dilution Antifungal Susceptibility Testing of Yeast, M27. 2017;46.

    Not in our library

  272. 272.

    Institute C.a.L.S. Reference Method for Broth Dilution Antifungal Susceptibility Testing of Filamentous Fungi, Approved Standard, M38. 2017;Volume 37:46.

    Not in our library

  273. 273.

    Fernandez-Silva F., Capilla J., Mayayo E., Guarro J. Modest efficacy of voriconazole against murine infections by Sporothrix schenckii and lack of efficacy against Sporothrix brasiliensis. Mycoses. 2014;57:121-124.

    Not in our library10.1111/myc.12112

  274. 274.

    Mario D.N., Guarro J., Santurio J.M., Alves S.H., Capilla J. In vitro and in vivo efficacy of amphotericin B combined with posaconazole against experimental disseminated sporotrichosis. Antimicrob. Agents Chemother. 2015;59:5018-5021.

    Not in our library10.1128/aac.00052-15

  275. 275.

    Fichman V., Valle A.C.F.d., de Macedo P.M., Freitas D.F.S., Oliveira M.M.E.d., Almeida-Paes R., Gutierrez-Galhardo M.C. Cryosurgery for the treatment of cutaneous sporotrichosis in four pregnant women. PLoS Negl. Trop. Dis. 2018;12:e0006434.

    Not in our library10.1371/journal.pntd.0006434

  276. 276.

    Ferreira C.P., do Valle A.C., Freitas D.F., Reis R., Galhardo M.C. Pregnancy during a sporotrichosis epidemic in Rio de Janeiro, Brazil. Int. J. Gynaecol. Obs. 2012;117:294-295.

    Not in our library10.1016/j.ijgo.2012.02.003

  277. 277.

    Legabão B.C., Fernandes J.A., de Oliveira Barbosa G.F., Bonfim-Mendonça P.S., Svidzinski T.I.E. The zoonosis sporotrichosis can be successfully treated by photodynamic therapy: A scoping review. Acta Trop. 2022;228:106341.

    Not in our library10.1016/j.actatropica.2022.106341

  278. 278.

    Borba-Santos L.P., Gagini T., Ishida K., de Souza W., Rozental S. Miltefosine is active against Sporothrix brasiliensis isolates with in vitro low susceptibility to amphotericin B or itraconazole. J. Med. Microbiol. 2015;64:415-422.

    Not in our library10.1099/jmm.0.000041

  279. 279.

    Fischman Gompertz O., Rodrigues A.M., Fernandes G.F., Bentubo H.D., de Camargo Z.P., Petri V. Atypical clinical presentation of sporotrichosis caused by Sporothrix globosa resistant to itraconazole. Am. J. Trop. Med. Hyg. 2016;94:1218-1222.

    Not in our library10.4269/ajtmh.15-0267

  280. 280.

    Nakasu C.C.T., Waller S.B., Ripoll M.K., Ferreira M.R.A., Conceição F.R., Gomes A.D.R., Osório L.D.G., de Faria R.O., Cleff M.B. Feline sporotrichosis: A case series of itraconazole-resistant Sporothrix brasiliensis infection. Braz. J. Microbiol. 2021;52:163-171.

    Not in our library10.1007/s42770-020-00290-5

  281. 281.

    Waller S.B., Dalla Lana D.F., Quatrin P.M., Ferreira M.R.A., Fuentefria A.M., Mezzari A. Antifungal resistance on Sporothrix species: An overview. Braz. J. Microbiol. 2021;52:73-80.

    Not in our library10.1007/s42770-020-00307-z

  282. 282.
    Sporotrichosis refractory to conventional treatment: therapeutic success with potassium iodide, · 2021
    Not checked
  283. 283.

    Poester V.R., Basso R.P., Stevens D.A., Munhoz L.S., de Souza Rabello V.B., Almeida-Paes R., Zancopé-Oliveira R.M., Zanchi M., Benelli J.L., Xavier M.O. Treatment of human sporotrichosis caused by Sporothrix brasiliensis. J. Fungi. 2022;8:70.

    Not in our library10.3390/jof8010070

  284. 284.

    Bernardes-Engemann A.R., Tomki G.F., Rabello V.B.d.S., Almeida-Silva F., Freitas D.F.S., Gutierrez-Galhardo M.C., Almeida-Paes R., Zancopé-Oliveira R.M. Sporotrichosis caused by non-wild type Sporothrix brasiliensis strains. Front. Cell. Infect. Microbiol. 2022;12:893501.

    Not in our library10.3389/fcimb.2022.893501

  285. 285.

    Lee Y., Puumala E., Robbins N., Cowen L.E. Antifungal drug resistance: Molecular mechanisms in Candida albicans and beyond. Chem. Rev. 2021;121:3390-3411.

    Not in our library10.1021/acs.chemrev.0c00199

  286. 286.

    Koehler A., Pagani D.M., da Silva Hellwig A.H., Scroferneker M.L. In-vitro antifungal susceptibility of the genus Sporothrix and correlation with treatment options for sporotrichosis: A systematic review. Rev. Med. Microbiol. 2021;32:219-227.

    Not in our library10.1097/mrm.0000000000000291

  287. 287.

    Gagini T., Borba-Santos L.P., Messias Rodrigues A., Pires de Camargo Z., Rozental S. Clotrimazole is highly effective in vitro against feline Sporothrix brasiliensis isolates. J. Med. Microbiol. 2017;66:1573-1580.

    Not in our library10.1099/jmm.0.000608

  288. 288.

    Fichman V., Marques de Macedo P., Francis Saraiva Freitas D., Carlos Francesconi do Valle A., Almeida-Silva F., Reis Bernardes-Engemann A., Zancopé-Oliveira R.M., Almeida-Paes R., Clara Gutierrez-Galhardo M. Zoonotic sporotrichosis in renal transplant recipients from Rio de Janeiro, Brazil. Transpl. Infect. Dis. 2021;23:e13485.

    Not in our library10.1111/tid.13485

  289. 289.

    Georgopoulos A., Petranyi G., Mieth H., Drews J. In vitro activity of naftifine, a new antifungal agent. Antimicrob. Agents Chemother. 1981;19:386-389.

    Not in our library10.1128/aac.19.3.386

  290. 290.

    Artunduaga Bonilla J.J., Honorato L., Haranahalli K., Gremião I.D.F., Pereira S.A., Guimarães A., Baptista A.R.S., Patricia d.M.T., Rodrigues M.L., Miranda K., et al. Antifungal activity of Acylhydrazone derivatives against Sporothrix spp. Antimicrob. Agents Chemother. 2021;65:e02593-20.

    Not in our library10.1128/aac.02593-20

  291. 291.

    Borba-Santos L.P., Visbal G., Braga T.G., Rodrigues A.M., De Camargo Z.P., Bezerra L.L., Ishida K., De Souza W., Rozental S. ∆24-sterol methyltransferase plays an important role in the growth and development of Sporothrix schenckii and Sporothrix brasiliensis. Front. Microbiol. 2016;7:311.

    Not in our library10.3389/fmicb.2016.00311

  292. 292.

    Borba-Santos L.P., Nucci M., Ferreira-Pereira A., Rozental S. Anti-Sporothrix activity of ibuprofen combined with antifungal. Braz. J. Microbiol. 2021;52:101-106.

    Not in our library10.1007/s42770-020-00327-9

  293. 293.

    Borba-Santos L.P., Ishida K., Calogeropoulou T., Souza W., Rozental S. Adamantylidene-substituted alkylphosphocholine TCAN26 is more active against Sporothrix schenckii than miltefosine. Mem. Do Inst. Oswaldo Cruz. 2016;111:523-527.

    Not in our library10.1590/0074-02760160088

  294. 294.

    Asquith C.R.M., Machado A.C.S., de Miranda L.H.M., Konstantinova L.S., Almeida-Paes R., Rakitin O.A., Pereira S.A. Synthesis and identification of pentathiepin-based inhibitors of Sporothrix brasiliensis. Antibiotics. 2019;8:249.

    Not in our library10.3390/antibiotics8040249

  295. 295.

    Gopinath P., Yadav R.K., Shukla P.K., Srivastava K., Puri S.K., Muraleedharan K.M. Broad spectrum anti-infective properties of benzisothiazolones and the parallels in their anti-bacterial and anti-fungal effects. Bioorg. Med. Chem. Lett. 2017;27:1291-1295.

    Not in our library10.1016/j.bmcl.2017.01.027

  296. 296.

    Azevedo-França J.A., Granado R., de Macedo Silva S.T., Santos-Silva G.D., Scapin S., Borba-Santos L.P., Rozental S., de Souza W., Martins-Duarte É S., Barrias E., et al. Synthesis and biological activity of novel zinc-itraconazole complexes in protozoan parasites and Sporothrix spp. Antimicrob. Agents Chemother. 2020;64:e01980-19.

    Not in our library10.1128/aac.01980-19

  297. 297.

    de Azevedo-França J.A., Borba-Santos L.P., de Almeida Pimentel G., Franco C.H.J., Souza C., de Almeida Celestino J., de Menezes E.F., Dos Santos N.P., Vieira E.G., Ferreira A., et al. Antifungal promising agents of zinc(II) and copper(II) derivatives based on azole drug. J. Inorg. Biochem. 2021;219:111401.

    Not in our library10.1016/j.jinorgbio.2021.111401

  298. 298.

    Gagini T., Colina-Vegas L., Villarreal W., Borba-Santos L.P., de Souza Pereira C., Batista A.A., Kneip Fleury M., de Souza W., Rozental S., Costa L.A.S., et al. Metal–azole fungistatic drug complexes as anti-Sporothrix spp. agents. New J. Chem. 2018;42:13641-13650.

    Not in our library10.1039/c8nj01544a

  299. 299.

    Tandon V.K., Kumar S., Mishra N.N., Shukla P.K. Micelles catalyzed chemo- and regio-selective one pot and one step synthesis of 2,3,5,6-tetrakis(alkyl and arylsulfanyl)-1,4-benzoquinones and 2,5-diaminosubstituted-1,4-benzoquinones “In-Water” and their biological evaluation as antibacterial and antifungal agents. Eur. J. Med. Chem. 2012;56:375-386.

    Not in our library10.1016/j.ejmech.2012.07.022

  300. 300.

    Brilhante R.S., Silva N.F., Marques F.J., Castelo-Branco Dde S., de Lima R.A., Malaquias A.D., Caetano E.P., Barbosa G.R., de Camargo Z.P., Rodrigues A.M., et al. In vitro inhibitory activity of terpenic derivatives against clinical and environmental strains of the Sporothrix schenkii complex. Med. Mycol. 2015;53:93-98.

    Not in our library10.1093/mmy/myu085

  301. 301.

    Brilhante R.S., Malaquias A.D., Caetano E.P., Castelo-Branco Dde S., Lima R.A., Marques F.J., Silva N.F., Alencar L.P., Monteiro A.J., Camargo Z.P., et al. In vitro inhibitory effect of miltefosine against strains of Histoplasma capsulatum var. capsulatum and Sporothrix spp. Med. Mycol. 2014;52:320-325.

    Not in our library10.1093/mmy/myt027

  302. 302.

    Borba-Santos L.P., Vila T., Rozental S. Identification of two potential inhibitors of Sporothrix brasiliensis and Sporothrix schenckii in the Pathogen Box collection. PLoS ONE. 2020;15:e0240658.

    Not in our library10.1371/journal.pone.0240658

  303. 303.

    Borba-Santos L.P., Barreto T.L., Vila T., Chi K.D., Dos Santos Monti F., de Farias M.R., Alviano D.S., Alviano C.S., Futuro D.O., Ferreira V., et al. In vitro and in vivo antifungal activity of buparvaquone against Sporothrix brasiliensis. Antimicrob. Agents Chemother. 2021;65:e0069921.

    Not in our library10.1128/aac.00699-21

  304. 304.

    Brilhante R.S., Pereira V.S., Oliveira J.S., Lopes R.G., Rodrigues A.M., Camargo Z.P., Pereira-Neto W.A., Castelo-Branco D.S., Cordeiro R.A., Sidrim J.J., et al. Pentamidine inhibits the growth of Sporothrix schenckii complex and exhibits synergism with antifungal agents. Future Microbiol. 2018;13:1129-1140.

    Not in our library10.2217/fmb-2018-0070

Reads

Read by people on this page

None yet.

Checked or read by AI through naulon

None yet.

A person counts once a day per paper. We keep no cookie and no address: a reader is a hash that changes every day. Any month under five reads shows no number.

Are you an author?

Is this your paper?

Claim it to add your note and be paid when agents cite it. Free.